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ABSTRACT
In many human cancers, p27 down-regulation correlates to a worse prognosis suggesting that 
p27  levels  could  represent  an  important  determinant  in  cell  transformation  and  cancer 
development. Using a mouse model system based on v-src-induced transformation, we show 
that p27 absence is linked to a more aggressive phenotype, with an increased cell growth and 
motility. In 3D systems, transformed p27null fibroblasts shift from a mesenchymal spindle-
like  shape  to  a  more  rounded  cell  morphology,  accompanied  by  amoeboid-like  morph-
dynamics, membrane ruffling zones and loss of dendritic-like cell extensions. Importantly, the 
acquirement of amoeboid motility in p27-/- transformed cells is associated with a higher ability 
to move in and colonize distant sites, in vivo. The reintroduction of different p27 mutants in 
transformed  p27null  cells  clearly  demonstrates  that  the  control  of  cell  proliferation  and 
motility  by p27 represents  two distinct  functions,  both necessary to  fully  act  as  a  tumor 
suppressor. In fact, while the N-terminus region is necessary to block cell proliferation, p27 
controls cell shape and motility through its C-terminus domain. 
Interestingly,  both  the  proliferative  and  motile  advantage  displayed  by  v-src-transformed 
p27-/- cells  highlighted  also after  transformation  with the oncogene H-Ras,  suggesting the 
existence and the involvement of common pathways responsible for p27 functions.  
All together, our results demonstrate that p27 expression is an important determinant both in 
the first  steps of cell  transformation  and tumor  establishment  as well  as  in  the following 
progression to tumor  dissemination and colonization  of distant sites.  Moreover,  our study 
demonstrate for the first time that p27 can affect the motile and the invasive behavior by 
driving  and  regulating  cell  plasticity  that,  in  turn,  influences  tumor  cell  morphology and 
movement. 
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During the Ph.D. course I worked on  the role of the CKI p27kip1 in tumor cell growth and 
motility. In particular, I studied the role of p27 in cell proliferation, motility and invasion both 
in vitro and in mouse models in vivo. These studies led to the understanding that p27 was able 
to block not only cancer cell growth but also invasion and metastasis formation. In particular 
for the first time it was demonstrated that p27 can affect the motile and the invasive behavior 
by driving and regulating cell plasticity that, in turn, influences tumor cell morphology and 
movement. In this period, two papers describing most of the data presented in the PhD thesis 
are in preparation. 
Berton  S,  Belletti  B,  Wolf  K,  Lovat  F,  Colombatti  A, Friedl  P,  Baldassarre  G.  ”p27kip1 
expression regulates the switch from mesenchymal to amoeboid motility in v-src transformed 
fibroblasts”. 2008. In preparation.
Belletti B, Berton S, Pellizzari I, Fabris L, Wolf K, Lovat F, Schiappacassi M, D’Andrea S, 
Nicoloso MS, Colombatti A, Friedl P, Baldassarre G. “p27kip1 controls cell morphology and 
motility in 3D through the regulation of MT dynamics and vesicular trafficking”. 2008.  In 
preparation.
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first trimester human trophoblast functions”. Accepted for publication, 2008. Placenta.
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ABBREVIATIONS
ECM: extracellular matrix
2D: two-dimension/two-dimensional  
3D: three-dimension/three-dimensional
MMPs: matrix metallo-proteinases
EMT: epithelial-mesenchymal transition
MAT: mesenchymal–amoeboid transition
GEFs: guanine nucleotide exchange factors
GAPs: GTPase-activating proteins
MTs: microtubules
MTOC: microtubule organizing centre 
LOH: loss of eterozygosity
MEFs: mouse embryo fibroblasts
SFK: Src family kinase
RSV: Rous sarcoma virus
SH: SRC homology (domain)
ts: temperature sensitive
FATIMA: fluorescence-assisted transmigration assay
CAFCA: centrifugal assay for fluorescence-based cell adhesion
HRP: horseradish peroxidase
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Introduction
INTRODUCTION
1. Cell motility in 3D environment as a cue for metastatic process. 
Tumor metastasis represents the most common cause of death in cancer patients. Metastasis is 
a  multi-stage  process  involving  cancer  cell  motility,  intravasation,  transit  in  the  blood or 
lymphatic vessels, extravasation and growth at a new site (Fig1; Chambers et al., 2002; Sahai, 
2007). 
The acquisition of invasive behaviour is one of the first steps in the metastatic process and it 
is necessary to allow the cells to detach by primary tumor and enter the blood or lymphatic 
vasculature to spread to distant organs. Only a subset of tumour cells can overcome these 
diverse challenges, and therefore metastasis is generally an inefficient process (Wong et al., 
2001). Tumor cells dissemination is strictly linked to their ability to attach to and move within 
the Extracellular Matrix (ECM). 
Both in physiological and in pathological conditions cells migrate through three-dimensional 
(3D) environments, thus experimental systems that reproduce the 3D setting could well mimic 
the in vivo situation. Further, using 3D experimental model systems it has been revealed that 
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Figure 1: Features of the metastatic process.  Metastasis development is a multi stage process that begins 
from the acquirement of motile and invasive properties in the tumor cell population. This is strictly influenced 
by ECM and micro-environment interactions  and by the interplay with non tumor cells,  such as resident 
fibroblasts or immune cells. The second step is represented by intravasation into blood or lymphatic vessel, 
necessary to reach distant organs and sites. Once the cells entered into the blood flow, they can attach to 
vessel wall and cancer cell extravasation can be observed. Cell will then undergo apoptosis, enter a state of 
dormancy or begin proliferation within or outside vessels giving rise to metastasis formation (modified from 
Sahai, 2007)  
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exists  a  higher  complexity  in  the  cell  migration  and  in  the  adaptation  responses  in  3D 
compared to the classical 2D environment (Friedl and Wolf, 2003; Wolf and Friedl, 2006; 
Sahai and Marshall, 2003; Cukierman et al., 2001). For example, the adhesive mechanisms 
are quite different in cells that move on the ECM substrates (2D) or through ECM lattices 
(3D). In fact,  fully mature focal contacts  have only been observed in cells that are firmly 
attached to 2D substrates, whereas when cells are placed in 3D substrates, integrins tend to 
cluster in less assembled focal interactions (Friedl and Wolf, 2003). Moreover, the speed and 
character  of  cell  motility  in  vivo is  quite  different  from  that  normally  observed  on  2D 
substrates  in vitro  (Condeelis and Segall, 2003).  In vivo in fact, cancer cells move at high 
speeds (up to 15µm a minute) and can change shape and direction rapidly, whereas, in 2D 
cultures,  the more  adhesive interactions  reduce the migration  speed and the possibility to 
switch between different migration mechanisms (Condeelis and Segall, 2003). 
A  five-step  model  of  cell  migration  in  2D  was  well  established  over  the  past  30  years 
(Lauffenburger and Horwitz, 1996) but this model does not perfectly fit with 3D-motility. For 
example,  when a cell  moves  in a 3D environments  an additional  important  feature is  the 
proteolytic remodelling of the ECM (Friedl and Wolf, 2003). 
The first step in 3D migration is represented by the protrusion formation at the leading edge. 
For this process it is necessary that the actin polymerizes by coupling to the actin-nucleating 
ARP2/3  complex  and  the  multifunctional  adaptor  protein  WASP.  The  ARP2/3-WASP 
complex is linked to the inner leaflet of the plasma membrane via clustered phosphoinosites 
and here  can  interact  with  actin  filaments  and  induce  their  branching.  During  protrusion 
formation, the integrinic receptors come in contact with ECM ligands and cluster in plasma 
membrane.  Clustered integrins recruit  adaptor and signaling proteins via their  intracellular 
domains, thereby inducing phosphorylation and dephosphorylation signals into the cell and 
stabilizing focal contacts. 
The assembly of focal  contacts  is  also directly  or indirectly  induced by several  signaling 
pathways,  such as PI3K, PKC and RhoGTPases. Before and while focal contacts develop, 
actin filaments locally elongated and assemble, through the action of crosslinking proteins, 
such  as  α-actinin  and myosin  II.  The branched actin  networks  below the inner  leaflet  of 
plasma  membrane  are  termed  cortical  actin,  whereas  cytoplasmic  bundles  and  elongated 
cables of actin filaments are termed stress fibres. After the focal contact formation, surface 
proteases  become  concentrated  near  substrate  binding  sites.  Here  proteases  cleave  ECM 
components, such as collagen, fibronectin, laminins and pro-MMPs obtaining active soluble 
MMPs and inducing a focalized proteolysis of the matrix. 
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The fourth step is represented by cell  contraction induced by the actin-myosin II binding. 
Active myosin II binds to actin filaments and generates actomyosin contraction that, in turn, 
promotes the shortening of cell’s length axis and generates inward tension. By several and not 
completely understood mechanisms, cell substrate linkages resolve preferentially in the back 
of the cells, whereas the leading edge remains attached to the ECM. Myosin II is activated by 
myosin light chain (MCL) that in turn is phosphorylated by the myosin light chain kinase. On 
the  contrary,  the  MLC  phosphatase,  that  is  inhibited  by  the  Rho  effector  ROCK, 
dephosphorylates  MLC  thus  inhibiting  actomyosin  contraction.  Following  focal  contact 
disassembly,  the  trailing  edge,  together  with the  cell  body and the  nucleus,  slowly glide 
forward (Friedl and Wolf, 2003). 
In vitro and  in vivo observations have shown that tumor cells possess a broad spectrum of 
migration mechanisms to infiltrate the  surrounding tissue matrices (Friedl and Wolf, 2003; 
Friedl 2004). They can disseminate as single cells, referred to as “individual cell migration” 
or expand in solid cell strands, sheets, files or clusters, called “collective migration” (Friedl 
and Wolf, 2003). 
In  many  tumors,  both  single  cells  and  collectives  are  simultaneously  present.  Whereas 
leukemias,  lymphomas  and most  solid  stromal  tumors,  such as  sarcomas,  disseminate  via 
single cells,  epithelial  tumors  commonly use collective migration mechanisms  (Friedl  and 
Wolf, 2003). 
Between  the  so  called  “individual  migration”,  the  mesenchymal  and  the  amoeboid 
mechanisms are the most known. Mesenchymal migration, typical of fibroblasts, is mainly 
found  in  cells  from  connective  tissue-tumors,  such  as  fibrosarcomas,  gliomas  and  de-
differentiated epithelial cancers and it is characterized by a fibroblast-like spindle shape (Wolf 
et al., 2003; Friedl and Wolf, 2003). It is dependent on integrin-mediated adhesion dynamics 
and on proteases focalization and it is characterized by a relative low velocity  (Friedl and 
Wolf, 2003). 
The  amoeboid  motility  is  a  less  adhesive  mechanism and it  is  integrin  independent.  The 
mechanism is propulsive and the cells, highly deformable, are able to circumnavigate, rather 
than to degrade, the ECM barriers, moving faster than cells that use mesenchymal strategy 
(Table1; Friedl and Wolf, 2003; Wyckoff et al., 2006). 
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Mesenchymal and amoeboid migration are also characterized by a different involvement of 
small GTPases of the Rho family, even if many aspects are still not completely elucidated. 
High RhoA and Rho kinase (ROCK) activity seems associated with amoeboid motility, while 
mesenchymal migration needs localized RhoA degradation at the leading edge and high Rac 
activity to promote the extension of cellular protrusions (Sahai and Marshall, 2003; Webb and 
Horwitz, 2003). Further, it was demonstrated that the activity of calpain2 and the Src family 
kinases (which normally act upstream of calpain2 to induce integrin adhesion turnover) are 
important determinants for an optimal mesenchymal tumor invasion through fibrillar collagen 
or  Matrigel  matrix.  Conversely,  amoeboid  tumor  invasion  results  relatively  insensitive  to 
inhibition of these two molecular enzymes (Carragher et al., 2006).
Under certain circumstances, cancer cells can switch from a migration mechanism to another. 
This phenomenon could compensate for the loss of a particular motile ability and allows the 
cells  to  develop  migratory  escape  strategies.  Such  adaptation  responses  is  known  as 
“plasticity” or “transition” (Friedl and Wolf, 2003). 
The  most  well  known  example  of  changes  in  cancer  cell  migration  is  the  epithelial-
mesenchymal transition (EMT). Following the carcinoma progression and de-differentiation, 
ephitelial cells switch from a collective invasion pattern towards a detached and disseminated 
cell migration mechanism. In this meaning, EMT represents an example of phenotypic and 
functional plasticity that spontaneously occurs during the course of tumor progression (Friedl 
and Wolf, 2003). 
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Table1: Differences in cellular and molecular migration mechanisms (from Friedl and Wolf, 2003)
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Moreover,  cancer  cells  can  also  undergo  conversion  from  a  mesenchymal  towards  an 
amoeboid cell type, which is termed the mesenchymal–amoeboid transition (MAT) (Fig2). 
This transition is not only accompanied by a change in cell morphology (from fibroblast-like 
spindle-shaped towards rounded and eliptoid), but also results in altered integrin distribution, 
organization of the actin cytoskeleton, and changes in molecular strategies to overcome tissue 
barriers  (Friedl and Wolf, 2003). Several factors can lead to MAT, including abrogation of 
pericellular  proteolysis  by  protease  inhibitors,  weakening  of  cell–ECM  linkages,  and 
alterations in the RHO signalling pathways (Fig2; Friedl and Wolf, 2003). 
The  MAT  was  first  observed  in  HT-1080  fibrosarcoma  and  MDA-MB-231  mammary 
carcinoma cells after abrogation of pericellular proteolysis (Wolf et al., 2003). In 3D collagen 
matrices, in fact, highly invasive and metastatic HT1080 and MDA-MB-231 cancer cells use 
a mesenchymal migration strategy, but, after pharmacological inhibition of MMPs, they don’t 
cease to move neither become entrapped in the matrix. Conversely, cells acquire a protease-
independent migration that is characterized by cell alignment along pre-existing fibre strands, 
shape change and the ability to squeeze through narrow matrix regions (Wolf et al., 2003). 
More recently also an increased RhoA activity has been associated to the MAT both in vitro 
and in vivo (Sahai et al., 2007; Gadea et al., 2007). It was demonstrated that Smurf1 protein, 
through the regulation of peripheral RhoA–ROCK–MLC2 signaling, can regulate in vitro and 
in  vivo tumor  cell  motility  and invasion in  BE colon carcinoma cells  and MDA-MB-231 
(Sahai  et  al.,  2007).  Smurf1,  which  is  an  E3-ubiquitin  ligase,  induces  RhoA proteasome 
degradation at the leading edge, favouring the correct extension of cellular protrusions and the 
establishment of cell polarity (Wang et al., 2003; Sahai et al., 2007). Thus Smurf1 inhibition 
induces  the  transition  from  the  “path  generating”  mesenchymal  to  the  “path  finding” 
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Figure2: Plasticity of tumor invasion mechanisms: the mesenchymal-amoeboid transition. 
Disseminating cancer cells can undergo a variety of adaptation reactions in response to changes in their 
molecular migration programme. When proteases, such as MMPs, serine proteases and cathepsins are 
blocked or after changes in Rho GTPases activity, cells that use mesenchymal strategy can switch to the 
highly dynamic and protease-independent amoeboid migration (modified from Friedl and Wolf, 2003).
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amoeboid migration that is associated to high activities of Rho, ROCK, and MLC2 necessary 
to generate  cortical  contractile  forces used for matrix  deformation (Sahai  et  al.,  2007).  A 
recent work has shown also how p53 deficiency in mouse embryonic fibroblasts cultured in 
3D matrices induces a switch from an elongated spindle morphology to a markedly spherical 
and flexible one associated with highly dynamic membrane blebs (Gadea et al., 2007). 
In a recent study, it was shown that the non-metastatic breast cancer cells had a much more 
elongated  morphology  than  their  metastatic  counterparts  and,  interestingly,  conversion  of 
cells  that  normally  move  with  an  elongated  morphology  to  a  more  rounded morphology 
increased both their ability to move and to enter tumor vessels (Wyckoff et al., 2006). The 
authors showed  that amoeboid tumor cells  generate  sufficient actomyosin force to deform 
collagen fibers and are able to push through the ECM. This study suggests that tumor cells 
with an elongated morphology may need to adopt a more rounded shape, characterized by the 
increased cortical acto-myosin contraction, to efficiently intravasate within blood vessels and 
withstand greater mechanical stress (Wyckoff et al., 2006). 
Following introduction into the circulation,  tumor cells  rapidly lodge in capillaries (Fig1). 
Several different mechanisms for this arrest have been described, although their respective 
relevance to human disease is unclear. For example,  the arrest can simply be caused by the 
large physical size of tumor cells relative to the capillary lumen or alternatively, tumor cells 
can actively  adhere  to  endothelia  even when not  restricted  by the  diameter  of  the vessel 
(Sahai,  2007). After  the  attachment  of  tumor  cells  to  vessel  walls,  leukocytes  may  be 
recruited, and they are thought to be the first cells to extravasate and cancer cells following 
them. It was described that extravasation typically occurs a few hours after attachment to the 
vessel wall; cell protrusions and deformation of the nucleus has been observed crossing an 
endothelium, implying that it is an active process (Tsuji et al., 2006). It is likely that many of 
the same molecular mechanisms required for cell mobilization from the primary tumour will 
be used for extravasation,  but the  actin  remodelling  and protease  function have not  been 
investigated in detail in this step of metastatic process (Sahai, 2007). 
An important factor that determines the cell attachment and extravasation is the shear stress – 
the physical force exerted on cells in the vessels as a result of blood flow. Non-metastatic 
cells are generally more susceptible to shear stress and they are rapidly sheared and detached. 
Of course, the entity of the shear stress can vary considerably between tissues; for example, 
blood  pressure  in  liver  capillaries  is  low,  whereas  it  is  much  higher  in  muscle,  and  the 
morphologies of tumor cells arresting at these locations are correspondingly different (Sahai, 
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2007). However,  a  causal  link  between  local  blood  pressure  in  the  different  organs  and 
metastatic efficiency remains to be clarified.
Once tumor cells arrived at the secondary sites, most of them undergo apoptosis within 24 
hours (Fig1; Chambers et al., 2002). Non-metastatic cells are more prone to apoptosis than 
their  metastatic  counterparts,  indicating  that  increased  cell  survival  at  this  stage  of  the 
metastatic  process  correlates  with  overall  metastatic  capability  (Kim et  al.,  2004). Some 
oncogenes that promote cell proliferation and survival in the primary tumor are also shown to 
be involved in promoting the survival of cancer cells at metastatic sites. For example,  the 
overexpression of BCL2 or active HRAS increased the survival and proliferation of cells that 
had lodged within lungs and the liver, respectively (Wong et al, 2001). Moreover,  various 
external factors contribute to reduced tumor cell survival at metastatic sites. For example, the 
lack of the normal pro-survival adhesion signals present in the tissue of origin of the cancer 
cells may lead to anoikis, the so called apoptosis induced by lack of attachment to a substrate, 
or tumor cells may be cleared by immune cells (Sahai, 2007). 
Not all the cells that survive at secondary sites will begin to proliferate because not all tumor 
cells have the same replicative potential. A new model suggests that only when the so called 
'cancer stem cell' (described as a cell that is able to self-renew and to divide giving rise to 
another  malignant  cell)  arrives  at  a  secondary  site,  macroscopic  metastasis  are  formed 
(Bjerkvig  et  al.,  2005).  In  all  other  cases  there  will  be  limited  or  no proliferation  of  the 
disseminated cells. 
Even if many aspects remain to understand, altogether the data collected and the advances in 
microscopy and imaging probes allowed us to dissect more in detail the metastatic process, 
till now considered a 'black box' research. 
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2. The RAS-GTPases superfamily in actin and tubulin cytoskeleton.
GTPases are molecular switches that control a wide variety of signal transduction pathways in 
all  eukaryotic  cells.  They are  known  mainly  for  their  pivotal  role  in  regulating  the actin 
cytoskeleton, but in the last decade many studies have revealed their ability to influence also 
cell polarity,  microtubule dynamics,  membrane transport pathways and transcription factor 
activity. Being GTPase enzymes, they use a simple biochemical strategy to control complex 
cellular processes. They cycle between two conformational states: one bound to GTP ('active' 
state), the other bound to GDP ('inactive' state) and they are able to hydrolyze GTP to GDP. 
In the 'on' (GTP) state, GTPases recognize target proteins and generate a response until GTP 
hydrolysis  returns the switch to the 'off'  state (Fig3). The RAS-GTPase superfamily is the 
most known family of these enzimes and mammalian cells contain several hundred GTPase 
switches. These small, monomeric GTPases fall into five major groups: Rho, Ras, Rab, Arf 
and Ran (Etienne-Manneville and Hall, 2002).
Rho activity is very carefully regulated and, for this family, in the human genome over 60 
activators  (GEFs)  and  over  70  inactivators  (GAPs)  are  expressed.  The  Rho gene  was 
identified in 1985, but only in 1992 some observations provided the first insights into the 
cellular  function  of  Rho  GTPases.  Constitutively  activated  mutants  of  Rho  and  Rac  (a 
member of the family) were found to induce respectively the assembly of contractile actin and 
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Figure3: The RhoGTPases cycle.  They cycle between an active (GTP-bound) and an 
inactive (GDP-bound) conformation. In the active state, they interact with one of over 60 
target proteins (effectors). All Rho GTPases are prenylated at their C terminus, and this is 
required for function. The cycle is highly regulated by three classes of protein: the guanine 
nucleotide exchange factors (GEFs), that catalyse nucleotide exchange and mediate 
activation; the GTPase-activating proteins (GAPs), that stimulate GTP hydrolysis, leading to 
inactivation; and the guanine nucleotide exchange inhibitors (GDIs) that extract the inactive 
GTPase from membranes (From Etienne-Manneville and Hall, 2002). 
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myosin  filaments  (stress  fibers)  and  actin-rich  surface  protrusions  (lamellipodia)  when 
introduced into fibroblasts (Ridley and Hall, 1992; Ridley et al., 1992; Nobes and Hall, 1999). 
Later, Cdc42, another member of this family, was shown to promote the formation of actin-
rich, finger-like membrane extensions (filopodia) (Nobes and Hall,  1995; Nobes and Hall, 
1999). The conclusion that Rho, Rac and Cdc42 regulate three separate signal transduction 
pathways linking plasma membrane receptors to the assembly of distinct actin structures has 
been confirmed in a wide variety of mammalian cell types as well as in yeast, flies and worms 
(Etienne-Manneville and Hall, 2002). But how these proteins work together to regulate cell 
migration is not so well defined and the picture appears more complicated. 
It has become a dogma that Rac and Cdc42 drive protrusion at the front of the cell, whereas 
Rho drives contraction at the rear and that there is an antagonistic relationship between Rac 
and Rho, with the two proteins suppressing each other's activities and phenotypes (Burridge 
and Doughman, 2006). This, however, has turned out to be a too simple model in some cases. 
For example,  although Rac and Cdc42 promote actin polymerization and extension of the 
leading edge of cells, Rho can also promote actin polymerization through its interaction with 
the protein mDia, and this can contribute to membrane extension (Higashida et al., 2004). In 
particular, a localized RhoA activation is required for the induction of membrane ruffling, the 
induction of which is a typical phenotype of activated Rac (Kurokawa and Matsuda, 2005). 
Nevertheless, the activity of Rho downstream effector ROCK has been shown to suppress cell 
protrusion in a variety of cells (Tsuji et al., 2002; Worthylake and Burridge, 2003; Xu et al., 
2003). Altogether these effectors and their spatial and temporal activation are required for cell 
polarization  during  migration  (Ridley et  al.,  2003).  Although localized  Rac-induced actin 
polymerization is considered the driving force, migration may be facilitated by other cellular 
activities. The microtubule cytoskeleton, for example, is highly polarized during migration. 
Microtubules are polymers composed of  α/β tubulin heterodimers that continuously switch 
between  phases  of  polymerization  and  depolymerization,  a  property  known  as  dynamic 
instability (Rubin and Atweh, 2004). The transition from a phase of growth to a phase of 
shrinkage is called ‘catastrophe’, while the transition from a phase of shrinkage to a phase of 
growth is called ‘rescue’. In interphase, microtubules are long and relatively stable and their 
dynamics of growth and shrinkage are relatively slow. In contrast, at the onset of mitosis, 
when the interphase arrays of microtubules depolymerize and then repolymerize to assemble 
the mitotic spindle, microtubules are highly dynamic as a result of a marked increase in their 
rate of catastrophe (Rubin and Atweh, 2004).
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The most striking polarization of the microtubule cytoskeleton in many migrating cells is the 
orientation  of  the  centrosome, the  organizing  centre  of  the  radial  interphase  microtubule 
network (MTOC), either in front of or behind the nucleus, with respect to the direction of 
migration and respect to the cell type (Fig4; Yvon et al., 2002; Etienne-Manneville and Hall, 
2002). Partly as a result of centrosome position, microtubules themselves are polarized and 
tend to be aligned along the axis  of cell  migration;  many of them,  particularly stabilized, 
detyrosinated microtubules, are preferentially oriented with their plus ends facing the leading 
edge (Fig4; Wittmann and Waterman-Storer, 2001). Many observations have suggested that 
microtubules are required to establish cell polarity during motility.  For example fibroblasts 
require an intact microtubule cytoskeleton to maintain their polarization and, in neurons, it is 
fundamental to axonal growth (Wittmann and Waterman-Storer, 2001). 
There are three major hypotheses suggesting how microtubules contribute to cell polarity and 
migration.  First,  microtubules  could  serve as  tracks  for  directed  membrane  and organelle 
transport towards the leading edge of the cell providing building material for the protruding 
lamellipodium. Second, growing microtubules could directly promote lamellipodial protrusion 
and stabilize the leading edge to maintain a directed movement of the cell. Third, microtubules 
do not regulate protrusion but instead locally regulate adhesion and contraction. But besides 
these  hypothesis,  direct  evidence  suggests  that  Rho  GTPases  might  also  influence  the 
organization and  dynamics  of  microtubules  and,  conversely,  a  microtubule-dependent 
regulation  of  Rho GTPases  exists  (Wittmann  and  Waterman-Storer,  2001).  The 
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Figure4:  Microtubule polimerization in a 
migrative cell. a)  In many cell types, the 
centrosome reorients towards the  direction of 
migration (black arrow). b) Stable, detyrosinated
microtubules (in blue) appear to be oriented 
preferentially in the direction of migration. c) 
Microtubules exhibit net growth near the leading 
edge and, d)  as a result of actin-dependent 
retrograde flow (orange arrow) buckle and break 
in the cell body, creating depolymerising 
microtubule minus ends and dynamic plus ends. 
e)  Microtubule plus-end-binding proteins that 
might stabilize growing microtubule ends in the 
leading edge. The open arrow indicates the 
direction of cell migration. Thick black lines 
represent microtubules. Green and red arrows 
indicate growing or shrinking microtubules, 
respectively, and plus and minus signs indicate 
microtubule polarity (from Wittmann and 
Waterman-Storer, 2001).
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depolymerization of microtubules induces formation of contractile  actin  bundles and focal 
adhesions and increases the level of GTP-bound RhoA, whereas the induction of microtubule 
polymerization  leads  to lamellipodia  formation  and  activation  of  Rac1  (Wittmann  and 
Waterman-Storer,  2001).  Moreover,  Rho  (acting  through  p160Rho  kinase  and  mDia) 
promotes  the  accumulation  of  detyrosinated  microtubules,  Rac  (acting  through  p65Pak) 
inactivates the microtubule destabilizing protein, stathmin and Cdc42 regulate the orientation 
of the MTOC (Etienne-Manneville and Hall, 2002).
Besides  the  RhoGTPase  family,  with  RhoA,  Rac1 and Cdc42  as  most  studied  members, 
RasGTPase  proteins  and  their  signaling  pathways  have  been  extensively  studied. The 
RasGTPases  were  discovered  as  proteins  encoded  by  retroviral  oncogenes  that  had  been 
hijacked from the host genome by the Kirsten (K-RAS) and Harvey (H-RAS) rat sarcoma 
viruses.  The  prototypical  RAS  GTPase  proteins  -H-RAS,  N-RAS  and  K-RAS-  were  so 
identified  as  the  products  of  active  oncogenes  in  human  tumours,  even  if  they  primary 
contribute to cell-cycle regulation in normal, non-transformed cells. H-RAS, N-RAS and K-
RAS are highly related proteins, sharing approximately 84% identity,  and their divergence 
being  almost  exclusively  confined  to  the  carboxyl  terminus.  Although  there  might  be 
differences in the signalling pathways that they activate and in their subcellular distribution, 
these three proteins show similar functions. Ras GTPases are targeted to endosomes, Golgi 
stacks, the plasma membrane and mitochondria, where they are constitutively associated by 
means of farnesylation and palmitoylation (Ten Klooster and Hordijk, 2007). 
Human tumours  very frequently  express  RAS proteins  that  have  been  activated  by point 
mutation:  30% of all  tumours  have undergone an activating  mutation  in  one of  the RAS 
genes, with K-Ras mutations almost ubiquitous in pancreatic tumors and common in lung and 
colorectal cancer, H-Ras mutations has been found in bladder and kidney cancer and N-Ras 
mutations is common in leukemias (Table2; Bos, 1989; Downward, 2003).
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Table2: Activation of RAS pathway in 
different  tumors  (Modified  from 
Downward, 2003)
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In these tumours, the activated RAS protein contributes significantly to several aspects of the 
malignant  phenotype,  including  the  deregulation  of  tumour-cell  growth,  programmed  cell 
death and invasiveness, and the ability to induce new blood-vessel formation (Shields et al., 
2000). 
Early studies established the central position of the prototypical RAS GTPases in cell-cycle 
regulation. Microinjection  of  RAS-neutralizing  antibodies,  or  introduction  of  a  dominant-
negative form of RAS, blocked growth-factor-induced S-phase entry (Mulcahy et al., 1985; 
Stacey et al., 1991). Conversely, quiescent non-proliferating cells could be pushed back into 
the cell cycle by the microinjection of oncogenic H-Ras protein, independently of growth-
factor  stimulation  (Feramisco  et  al.,  1984).  Downstream of  RAS GTPases,  the  cell-cycle 
regulation  is  mediated  by  a  three-component  mitogen-activated  protein  kinase  (MAPK) 
cascade,  consisting  of  the  RAF,  MEK  (MAPK  and  extracellular  signal-regulated  kinase 
(ERK)  kinase)  and  ERK/MAPK  proteins.  In  addition,  the  phosphatidylinositol  3-kinases 
(PI3Ks) and the RAL-activating RALGDS proteins also signal downstream of RAS. 
The  main function of RAS in G1–S-phase progression is to inactivate RB and relieve cells 
from its growth-inhibitory actions: both the ERK/MAPK and the PI3K pathways make key 
contributions  to  RB inactivation.  Moreover,  RAS signalling  elevates  cyclin-D1 levels  by 
influencing the transcription, translation and protein stability of cyclin D1 and induced down-
regulation of p27 CKI expression through transcriptional and post-transcriptional mechanisms 
in  a  mitogen-dependent  way.  Ras,  via  the  PI3K  pathway,  regulates  p27  expression  by 
inactivating members of the forkhead transcription-factor family (Medema et al., 2000). PI3K 
pathway is also involved in the proteasome-mediated degradation of p27, possibly through the 
transcriptional  induction  of  Skp2,  the  F-box  protein  that  specifically  recognizes  p27 
(Mamillapalli  et  al.,  2001).  RAS-mediated  activation  of  the  RAF-MEK-ERK/MAPK 
pathway, moreover, reduces p27 levels through enhanced proteolysis and decreased protein 
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synthesis both in a CDK2 dependent and independent way (Delmas et al., 2001; Rivard et al., 
1999).
Ras signaling pathways are well known for their involvement in tumour initiation, but less is 
known about their contribution to invasion and metastasis. Most models of cell motility place 
Ras proteins as upstream regulators of Rho family proteins, controlling the activation states of 
RhoA, Rac1, and cdc42 in response to growth factor or cytokine stimulation (Bar-Sagi and 
Hall, 2000). For example, K-Ras, more efficiently than H-Ras, is able to stimulate both cell 
motility and Rac1 activation in fibroblasts (Walsh and Bar-Sagi, 2001). Activation of a Ras-
Raf-MAPK  cascade  was  also  shown  to  stimulate  motility  in  fibroblasts  through  calpain 
activation and subsequent rear detachment (Glading et al., 2000). In COS cells, Ras mediated 
downstream activation of MAP kinase cascade, was shown to be necessary for cell motility, at 
least in part through its effects on myosin light chain phosphorylation status (Klemke et al., 
1997; Cheresh et al., 1999). In breast epithelial cells, activated R-Ras was shown to stimulate 
migration  in  a  PI3K  and  PKC  dependent  way  (Keely  et  al.,  1999).  Moreover,  the  Ras-
activated Raf-MEK-ERK pathway can specifically control the expression of integrin receptors 
in a variety of human and murine cell lines, inducing changes in cell adhesion and migration 
(Woods et al.,  2001). Ras can also control cell  motility by regulating focal adhesions and 
stress fibres formation and it is seems to be involved in the epithelial-mesenchymal transition 
in a variety of cell lines (Nobes and Hall, 1999; Huber et al., 2005). Moreover, in some Ras-
transformed  cancer  cells,  including  epithelial  cancer  and  transformed  fibroblasts,  lack  of 
stress fibre formation has been correlated to the Rac-dependent induction of an amoeboid-like 
behaviour,  accompanied  by high migration  velocity  both in  vitro  and in vivo (Friedl  and 
Wolf, 2003). 
As suggested by these data and given the growing number of Ras effectors, it is not surprising 
that Ras can regulate cell motility interfering with many downstream pathways and using a 
variety of mechanisms, that only in part are elucidated (Oxford and Theodorescu, 2003) .
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3. p27Kip1 and cell cycle: a finely designed picture.
Besides cell migration and motility, ECM is essential also for cell survival and proliferation. 
The cell-ECM contact induces the activation of several signaling pathways that control cell 
cycle progression (Giancotti and Ruoslahti, 1999). The mitotic cell cycle is a tightly regulated 
universal process that ensure the correct division of one cell into two daughter cells and that 
underlies the growth and development of all living organisms. To ensure proper progression 
through the cell cycle, cells have developed a series of checkpoints that prevent them from 
entering into a new phase until they have successfully completed the previous one (Hartwell 
and Weinert,  1989).  The progression along the different  phases of cell  cycle  is  positively 
regulated  by the  sequential  activation  of  the  so  called  cyclin  dependent  kinases  (CDKs), 
evolutionary  conserved  serine-threonine  kinases.  CDKs  are  activated  along  the  different 
phases by associating with their regulatory partner member of the cyclin family. Conversely 
their  activity  is  counteracted  by  small  proteins  known  as  CDK  inhibitors  (CKIs).  Two 
different families of CKIs exist, the INK4 and the Cip/Kip proteins. The INK4 (Inhibitors of 
CDK4) family includes p16INK4a, p15INK4b, p18INK4c and p19INK4d. All these members exert their 
inhibitory  activity  by  binding  to  the  CDK4  and  CDK6  kinases  and  preventing  their 
association with D-type cyclins. INK4 members are responsible for G1 cell cycle arrest and 
can block proliferation only through a functional pRB pathway. The Cip/Kip family includes 
p21Cip1, p27Kip1 and p57Kip2, all characterized by the presence of a conserved N-terminal region 
containing the cyclin-CDK binding domain,  whereby they interact with the regulatory and 
catalytic subunit of every complex (Fig5. Belletti et al., 2005).
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Figure5: Schematic representation of cell cycle regulation. (from Belletti et al., 2005)
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Among these inhibitors, p27Kip1 (hereafter p27) is well known for its role in G1-S transition. It 
interacts  with and inhibits  cyclinE-CDK2 and cyclinA-CDK2 activity,  blocking cell  cycle 
progression. The crystal structure of the human p27 bound to the phosphorylated cyclinA-
CDK2 complex revealed that p27 binds the complex as an extended structure interacting with 
both cyclin A and Cdk2 (Russo, 1996). On cyclin A, it binds in a groove formed by conserved 
cyclin box residues. On Cdk2, it binds and rearranges the amino-terminal lobe and also inserts 
into the catalytic cleft, mimicking the ATP (Russo, 1996). 
The human p27 gene (CDKN1B) resides in a region of chromosome 12p13 and contains two 
coding and one non coding exons. The murine cdkn1b gene is located in a syntenic region on 
distal chromosome 6 and is similar to the human p27 gene. The cDNA sequence is more than 
90% homologous  to  the  human  p27  cDNA  (Philipp-Staheli  et  al.,  2001).  p27  sequence 
contains 198 aminoacids (197 in mouse) and presents some regulatory domains. From the 
residue 153 to 169 is present a nuclear localization signals, while a leucine rich nuclear export 
signal,  responsible  for  p27  shuttling  from  nucleus  to  cytoplasm,  is  localized  between 
aminoacids 32-45.
p27 expression in normal  cultured cells  is  finely regulated  and high levels  of the protein 
induce the arrest in G1 phase and cells accumulation in G0. p27 levels increase in response to 
various stimuli  that  inhibit  cell  proliferation,  such as cell-cell  contact,  loss of adhesion to 
extracellular  matrix,  induction  of  differentiation  or  TGFβ,  INF-γ,  c-AMP,  rapamicin  and 
lovastatin treatments (Belletti et al., 2005). The exit from the quiescent status requires the 
down-regulation of p27, which in turn results in CDKs activation. The enforced expression of 
p27 in tumor cells could also result in apoptotic cell death, probably due to the conflicting 
signals between proliferation and block of cell cycle progression.
p27 is mainly regulated at post-translational level. In contrast, p27 mRNA is usually constant 
through out the whole cell cycle. p27 could be regulated by sequestering into higher order 
complexes with cyclinD-CDK4 after activation of the MAPK pathway, that promotes cyclin 
D transcription (Cheng et al., 1998; Susaki et al., 2007). Also the proto-oncogene c-Myc, by 
increasing the expression of cyclin D and cyclin E, is responsible for p27 sequestration and 
this molecular event appears essential for Myc-induced cell cycle progression (Vlach et al., 
1996). 
Moreover, p27 can be displaced in the cytoplasm, with consequent progression in cell cycle, 
after activation of the Raf-Mek-Erk and PI3K-Akt pathways in a phosphorylation-dependent 
manner (described afterwards in detail. Philipp-Staheli et al., 2001). 
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But  the  most  important  way  for  p27  regulation  seems  to  be  its  ubiquitin-proteasome 
dependent degradation (Fig6). 
p27  proteolysis  is  cytoplasmatic  and  phosphorylation-independent  in  early  G1,  but  it  is 
nuclear and phosphorylation-dependent in late S-G2 phase (Fig7). The G0-G1 degradation is 
mediated by the KPC complex (Kip1 ubiquitination-promoting complex), consisting of KPC1 
and KPC2 proteins, that interacts with and ubiquitinates p27 in the cytoplasm (Kamura et al., 
2004; Kotoshiba et al., 2005). The nuclear export of p27 by CRM1 is necessary for KPC-
mediated  proteolysis  and  the  recognition  by  CRM1 needs  p27 phosphorylation  on  Ser10 
(Kamura et al., 2004; Boehm et al., 2002; Ishida et al., 2002). Recently a role of cyclin D2 in 
p27 translocation from the nucleus into the cytoplasm for its KPC-dependent degradation was 
demonstrated (Susaki et al., 2007)
Instead, the S-G2 degradation is mediated by an SCF ubiquitin ligase, composed by Skp1, a 
cullin subunit called CulI, Rbx1/Roc1 and the F-box protein Skp2 that specifically recognizes 
p27 (Hara et al., 2001; Zeng et al., 2002). Skp2 binds to p27 and promotes its degradation 
- 20 -
Figure6: Intracellular pathways known to regulate p27 expression and function. (From 
Belletti et al., 2005)
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only when p27 is phosphorylated on the conserved Thr187 by cyclinE-CDK2 or cyclinA-
CDK2 complexes (Montagnoli et al., 1999; Carrano et al., 1999).
The kinases that determine p27 phosphorylation status are several and differently regulated 
(Fig8). The phosphorylation at S10 is mediated by the kinase interacting stathmin (hKIS), a 
nuclear protein that binds the C-terminal domain of p27 and phosphorylates it at S10 in vitro 
and in vivo, promoting its nuclear export to the cytoplasm. hKIS is activated by mitogens 
during G0/G1, and expression of hKIS overcomes growth arrest induced by p27 (Boehm et 
al., 2002). The involvement of mitogenic signals have suggested the hypothesis that also the 
MAPK pathway could promote p27 phosphorylation at S10 (Rodier et al., 2001). Moreover 
recently it was described also a role of Akt in this phosphorylation (Nacusi and Sheaff, 2006). 
The T187 of p27 is phosphorylated by the cyclinE-CDK2 and cyclinA-CDK2, thus a trimeric 
complex is necessary for p27 ubiquitination and degradation (Montagnoli et al., 1999). Other 
important phosphorylation sites of p27 are the T157 (not conserved in mouse) and the T198 
(T197 in mouse), both regulated by Akt (Motti et al., 2004; Motti et al., 2005). The T157 
residue  maps  within  the  nuclear  localization  signal  of  p27  and  the  Akt-induced  T157 
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Figure7: Mechanisms regulating p27 ubiquitin-dependent degradation (From Belletti et al., 2005).
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phosphorylation causes retention of p27 in the cytoplasm, precluding p27-induced G1 arrest 
(Viglietto et al., 2002; Shin et al., 2005). Also the PI3K/Akt dependent phosphorylation at 
T198 was initially described to contribute  to p27 cytoplasmic mislocalization,  since,  once 
phosphorylated, it is recognized by the 14-3-3 proteins family and retained in the cytoplasm 
(Fujita  et  al.,  2002;  Motti  et  al.,  2004).  Moreover,  it  has  been  demonstrated  that 
phosphorylation  at  T198  is  able  to  regulate  p27  stability  (Kossatz  et  al.,  2006). 
Phosphorylation of p27 at  T198 prevents ubiquitin-dependent degradation of free p27 and 
controls progression through the G1 phase by regulating the association of p27 with cyclin-
cdk complexes (Kossatz et al., 2006). 
Recently, it has been shown that the growth-state-dependent tyrosine phosphorylation of p27 
modulates its inhibitory activity in vivo (James et al., 2008). In fact, based on the observation 
that  p27  bound  to  cyclinD-CDK4  can  be  both  inhibitory  and  non-inhibitory,  it  was 
demonstrated  that  this  behaviour  is  due  to  p27  growth-state-dependent  tyrosine 
phosphorylation (James et al., 2008). In particular, two tyrosine residues (Y88 and Y89) in 
p27's  CDK  interaction  domain  are  phosphorylated  preferentially  in  proliferating  cells, 
converting  p27  to  a  non-inhibitor  state  (James  et  al.,  2008).  The  residue  Y88  can  be 
phosphorylated by the Src-family kinase Lyn and the oncogene product BCR-ABL (Grimmler 
et al., 2007). It was reported that Y88-phosphorylated p27 is also efficiently phosphorylated 
on T187 by Cdk2 and in turn its SCF-Skp2-dependent degradation is promoted, suggesting an 
explanation for premature p27 elimination in cells transformed by activated tyrosine kinases 
(Grimmler  et  al.,  2007).  Besides  the  phosphorylation  at  Y88,  the  oncogenic  kinase  Src 
regulates p27 stability through its phosphorylation at  tyrosine 74 and, in a less degree,  at 
tyrosine 89: also in this case, the phosphorylation facilitates p27 proteolysis (Fig8; Chu et al., 
2007). 
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Figure8: Regulatory phosphorylation sites in p27 aminoacidic sequence.
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3.1. p27 and tumors: the utility of knock out model.
Even though p27 has shown a new "dark side" displaying oncogenic functions in some less 
specialized cell types and in some circumstances (Sicinski et al., 2007; Besson et al., 2007; 
Besson et al., 2004; Denicourt et al., 2007), p27 is well known to be a tumor suppressor gene. 
But, while prototypic tumor suppressor genes follow the Knutson’s “two-hit” criterion, p27 is 
haplo-insufficient  for tumor suppression (Fero et  al.,  1998). Animals lacking one copy of 
Cdkn1b gene develop tumors  spontaneously late  in life  and are highly sensitive  to tumor 
induction  when  challenged  with  carcinogens,  displaying  increased  tumor  frequency  and 
decreased latency (Fero et al., 1998). Thus, a reduced dosage of p27, rather than its absolute 
absence, can contribute to cancer susceptibility. Nullizygous animals for p27 display a further 
increase in tumor rate and this observation lead many to defined p27 as a “dosage-dependent” 
tumor suppressor gene. 
The use of mouse models resulted extremely useful to address the question of whether p27 is 
a causal or a secondary effect of tumor development. p27-/- mice display increased body size 
of  about  20-30% respect  to  wild-type  littermates,  due  to  increased  cellularity  of  tissues, 
demonstrating a role of p27 in the control of tissue growth also in vivo (Fig9. Fero et al., 
1996; Nakayama et al., 1996; Kiyokawa et al., 1996). 
Accordingly with the dosage-dependency of tumor suppressive potential of p27, heterozygous 
mice showed about 50% of p27 protein expression and an intermediate phenotype in terms of 
weight. This suggests that also in vivo the control of proliferation and body size is extremely 
sensitive to the levels of p27 protein. Further, p27-/- mice are prone to spontaneous pituitary 
adenomas and develop multiple organ hyperplasia. Challenging with radiation or chemical 
carcinogens, p27-/- mice are susceptible to developing tumors in multiple tissues, including 
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Figure9:  p27wt  versus  p27ko  mouse.  p27ko  mice 
display  an  increase  in  body  size  of  about  20/30% 
compared to wild type mice (From Philipp-Staheli et al.,  
2001).
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adenomas and adenocarcinomas of the intestine and lung, granulosa cell tumors of the ovary 
and uterine tumors. In addition to a reduced tumor free survival, p27-heterozygous and null 
mice show increased tumor multiplicity in different sites. 
p27 deficiency enhances the malignancy and frequency of tumor formation in cooperation 
with several  oncogenic  stimuli,  pointing  to  p27 as  a  major  rate-limiting  factor  for  tumor 
progression.  For  example,  about  50%  of  PTEN+/- mice  develop  prostatic  intraepithelial 
neoplasia after 9 months from birth, but concomitant inactivation of p27 (that normally is not 
associated to prostatic cancer) in PTEN+/- mice leads to prostate adenocarcinoma with 100% 
of penetrance within 3 months from birth (Di Cristofano et  al.,  2001). Similar results are 
obtained when p27 deficiency is combined with loss of eterozygosity (LOH) for pRB locus, 
resulting  in  developing  of  pituitary  adenocarcinoma  and  high  grade  of  thyroid  C  cell 
carcinoma  (Park  et  al.,  1999).  Moreover,  Myc  over-expression  results  in  decreased  mice 
survival  when  associated  to  p27  deficiency  and  the  absence  of  p27  in  INK4a/ARF null 
background result in increased lethality, higher incidence of lymphomas and appearance of 
metastasis (Martin-Caballero et al., 2004). p27 results also as adjuvant and promoter of p53-
driven tumorigenesis, since their concomitant absence in mice induces an accelerated tumor 
development,  increased morbidity and the detection of tumor types  not observable  in p53 
single mutants (Philipp-Staheli et al., 2004). 
In  colon,  p27 null  background combined  with  ApcMin/+ accelerate  tumor  development  and 
increase tumor malignancy; loss of the CBP transcription factor in thymocytes, combined to 
p27+/- background, results in the development of T-cell lymphoma already after 13 weeks 
(compared to a 24 latency period in p27wt background) (Philipp-Staheli et al., 2002; Kang-
Decker et al., 2004). 
Together  these  data  demonstrate  that  at  least  in  mice,  p27  functionally  interacts  and 
collaborates  with  several  tumor  suppressor  genes  and oncogenes  to  reduce  the  malignant 
phenotype, supporting the idea that p27 represents a nodal point in tumor suppression. This 
could, at least in part, explains why loss of p27 is so often associated with tumor development 
and progression in human cancers.
An increased body of literature reports frequent p27 functional inactivation in human cancers. 
LOH for p27 is not uncommon in human malignancies,  but silencing or mutations of the 
remaining allele are very rare, which is consistent with the notion that p27 loss in tumors is 
mainly due to an accelerated proteolysis  (Belletti  et al.,  2005). Accordingly,  a plethora of 
studies  shows the involvement  of  p27 protein  reduction  or loss in  many tumors,  such as 
carcinomas of the colon, breast, prostate, lung and ovary as well as brain tumors, lymphomas 
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and soft tissue sarcomas (Belletti et al., 2005). Multivariate analyses show that reduced p27 
levels are of independent prognostic significance for many of these tumors (Belletti et al., 
2005). Other observations suggest that p27 in tumors can also be down-regulated by different 
mechanisms, as its cytoplasmic delocalization (Belletti et al., 2005).
3.2. p27 shows a role in cell migration.
Among the non-cell cycle dependent functions of p27, regulation of cell motility is one of the 
most  controversial.  This  function  requires  the  cytoplasmic  localization  of  p27  so  results 
dependent on all those mechanisms that rule p27 shuttling from nucleus to cytoplasm. Many 
authors have demonstrated a role of p27 in cell migration, but the conclusions appear at least 
apparently in contrast. It was shown that p27 stimulates the migration in cortical neurons, in 
hepatocellular  carcinoma  cells  and  in  mouse  embryonic  fibroblasts  where  it  induces 
rearrangements of the actin cytoskeleton (Kawauchi et al., 2006; Itoh et al., 2007; McAllister 
et  al.,  2003;  Besson  et  al.,  2004).  Conversely  p27  seems  to  reduces  cell  migration  in 
endothelial  cells,  vascular  smooth  muscle  cells,  mesangial  cells,  sarcoma tumor  cells  and 
normal  mouse  fibroblasts  (Daniel  et  al.,  2004; Goukassian et  al.,  2001;  Sun et  al.,  2001; 
Baldassarre et al., 2005). 
In particular, we have demonstrated that p27 expression inhibits the migration of HT-1080 
fibrosarcoma cells and murine fibroblasts and that the migration-inhibitory activity of p27 is 
localized to the C-terminal 28 amino acids of the protein (Baldassarre et al., 2005). Using a 
yeast  two-hybrid  assay,  we identified  stathmin  as  a  partner  protein  that  binds  to  p27 C-
terminus  and  confirmed  their  in  vivo interactions  in  HT-1080  sarcoma  cells,  pork  brain, 
mouse fetal brain and normal mouse fibroblasts adherent to fibronectin. 
Stathmin, also referred to as Op18, is a ubiquitous cytosolic phosphoprotein highly conserved 
among vertebrates: human and  Xenopus stathmin are 79% identical (Maucuer et al., 1993). 
The 149 amino acid protein plays an important role in regulating microtubule dynamics in 
both interphase and mitosis and so it is crucial for maintenance of cell shape, intracellular 
transport, cell motility and cell division. As described previously, microtubules continuously 
switch between phases of polymerization and depolymerization, a property known as dynamic 
instability (Rubin and Atweh, 2004). 
Microtubule dynamics are regulated by several families of proteins, including microtubule-
associated  proteins  (MAPs)  and  microtubule-destabilizing  proteins.  Stathmin  is  a  major 
microtubule-destabilizing protein that promotes microtubule depolymerization by two distinct 
mechanisms (Fig10; Howell et al., 1999; Rubin and Atweh, 2004). The first is a catastrophe-
- 25 -
Introduction
promoting microtubule-depolymerization activity that requires the N-terminal region of the 
stathmin molecule and is necessary for the regulation of the mitotic spindle. The second is a 
tubulin-sequestering activity that requires the C-terminal region and is mainly important in the 
regulation of microtubule dynamics during interphase (Howell et al., 1999; Rubin and Atweh, 
2004). 
Stathmin is negatively regulated by phosphorylation at  four serine residues, Ser16, Ser25, 
Ser38  and  Ser63  in  response  to  a  number  of  signals,  including  those  necessary  for  cell 
proliferation,  differentiation  and progression through the cell  cycle  (Cassimeris,  2002).  In 
particular,  stathmin  phosphorylation  seems  to  be necessary for  the  cells  to  enter  mitosis. 
Several studies have demonstrated that phosphorylation at Ser16 and Ser63 inhibit stathmin to 
a  greater  extent  than  phosphorylations  at  Ser25  and  Ser38  and  probably,  multiple 
phosphorylations  of  stathmin  serve  to  amplify  the  inhibition  of  this  protein's  activity 
(Cassimeris, 2002).
Besides its role in mitotic spindle formation, many literature data support the pro-migrative 
role  of  stathmin.  For  example,  the  RNA interference  inactivation  of  Drosophila stathmin 
expression resulted in germ cell migration arrest and induced important anomalies in nervous 
system development (Ozon et al., 2002). Stathmin expression is also required in border cells 
of the Drosophila ovary for normal migration (Borghese et al., 2006). Moreover, reducing the 
expression of stathmin with an antisense oligonucleotide, results in the inhibition of migration 
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Figure10:  Stathmin  regulation  of  microtubule  dynamics  Microtubules 
continuously switch between phases of polymerization and depolymerization. Stathmin 
can sequester  un-polymerized tubulin by binding two αβ-tubulin heterodimers,  thus 
diminishing the pool of tubulin available for polymerization. Stathmin can also bind to 
the end of polymerized microtubules and increase the rate of catastrophe by inducing a 
conformational change that promotes microtubule depolymerization. (From Rubin and 
Atweh, 2004)
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of new neurons from the sub-ventricular zone to the olfactory bulb via the rostral migratory 
stream, suggesting a role for stathmin in the migration of newborn neurons in the adult rodent 
brain (Jin et al., 2004). 
Accordingly, we have demonstrated that  p27, binding the C-terminus of stathmin, interferes 
with its ability to sequester tubulin, leading to increased microtubule stabilization that in turn 
impairs migration function. Also in our systems, in fact, stathmin has a pivotal role in cell 
migration  regulation:  stathmin-null  mouse  embryo  fibroblasts  (MEFs)  showed  migration 
defects  rescued  by  transfection  of  stathmin  cDNA  and  stathmin  inhibition  reduces  cell 
motility, while its over-expression increases migration in HT-1080 cells (Baldassarre et al., 
2005). But intriguingly,  in our system the stathmin activity in cell  migration results to be 
regulated  by  p27  expression  and  together  these  data  represent  the  first  indication  that 
cytoplasmic p27 regulates migration by a direct effect on microtubule dynamic via-stathmin 
(Iancu-Rubin and Atweh, 2005).
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4. The oncogenic v-Src and its normal mammalian counterpart c-Src.
Several oncogenes are able to induce mouse fibroblasts transformation. Among them, one of 
the most powerful is certainly v-Src, whose normal counterpart in the mammalian cell (c-Src,) 
was  the  first  proto-oncogene  to  be  discovered  in  the  vertebrate  genome  (Takeya  and 
Hanafusa,  1983).  The  viral  src  gene  of  Rous  sarcoma  virus  (RSV)  encodes  the  first 
recognized tyrosine kinase (Hunter and Sefton, 1980). Src is a member of a multigene family 
(the  prototype  Src  family  kinase  (SFK))  of  membrane-associated  non-receptor  tyrosine 
kinases that comprises nine members, some of which (Src, Fyn and Yes) are ubiquitous and 
some of which display more-restricted expression (Thomas and Brugge, 1997). 
4.1. Structure and regulation of Src
Both the avian and human forms of c-Src protein are composed of a unique amino-terminal 
domain,  four  SRC homology  (SH)  domains  and  a  C-terminal  tail  containing  a  negative-
regulatory tyrosine residue (Tyr527, chicken; Tyr530, human) (Xu et al., 1997). The functions 
of the N-terminal domain are not well defined, but mutations in this region seems to reduce 
the  transforming  potential  of  v-Src.  The  SH domains  consist  of  the  SH1 kinase  domain, 
containing the auto-phosphorylation site necessary for full Src activation (Tyr416, chicken; 
Tyr419, human); the SH2 domain, interacting with the negative-regulatory Tyr527/530; the 
SH3 domain, which interacts with the kinase domain in the inactive form of the protein; and 
the SH4 domain, which contains the myristoylation site, important for membrane localization 
(Fig11. Yeatman, 2004). 
As mentioned before, the C-terminal tail and the SH2 and SH3 domains are involved in the 
negative regulation of c-Src. Crystallographic studies have shown that interactions between 
the C-terminus and the SH2 domain, and between the kinase domain and the SH3 domain, 
cause the c-Src molecule to assume a closed configuration that hides the kinase domain and 
reduces  substrate  interaction  (Yamaguchi  and  Hendrickson,  1996).  Mutational  studies 
primarily  involving  the  avian  forms  of  Src,  have  clearly  elucidated  a  closed,  inactive 
conformation and an open, active state. The inhibitory residue (Tyr527/530) can bind to the 
SH2 domain when phosphorylated and Src results inactive. When dephosphorylated, Src is 
active and show the potential for autophosphorylation and for downstream interactions with 
Src substrates (Cooper et al., 1986). Thus, phosphatases that dephosphorylate human c-Src at 
Tyr530  can  bring about  activation,  even  when protein  levels  are  normal.  Instead,  the  C-
terminal phosphate of c-Src can be removed by several protein phosphatases. Protein tyrosine 
phosphatase-  (PTP ) has been shown to dephosphorylate the terminal tyrosine residue  in  
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vitro and  in vivo, and PTP1, SH2-containing phosphatase 1 (SHP1) and SHP2 might also 
regulate c-Src (Yeatman, 2004). The most direct evidence for a role in c-Src activation in 
cancer among these phosphatases is for PTP1B, which is present at higher levels in breast 
cancer cell lines and can dephosphorylate c-Src (Bjorge et al., 2000). Conversely, inactivation 
of c-Src by phosphorylation of the terminal tyrosine residue is now known to be performed by 
CSK and its homologue CHK, resulting in the closed, inactive c-Src conformation described 
above (Frame et al., 2002; Yeatman, 2004). In addition to Thy527 dephosphorylation, c-Src is 
also activated by the direct binding to the SH2 and SH3 domains of focal-adhesion kinase 
(FAK)  or  its  molecular  partner  CRK-associated  substrate  (CAS,  also  known as  p130CAS) 
(Yeatman, 2004). 
Moreover,  c-Src can also be activated as a result of a variety of extracellular  signals. For 
example, interactions with ligand-activated receptor tyrosine kinases, such as EGFR, PDGFR, 
ERBB2 (HER2/NEU), FGFR, CSF1 and HGF can result in augmented and even synergistic 
c-Src  activation.  In  particular,  the  activation  of  growth-factor  receptors  leads  to  their 
association with the SH2 domain, which disrupts inhibitory intramolecular interactions and 
promote  c-Src  activation  (Yeatman,  2004).  Other  modes  of  c-Src  regulation  include 
ubiquitination,  with subsequent degradation by the proteasome.  The CBL ubiquitin ligase, 
found deregulated in some cancer cells, has been shown to be important in suppressing v-Src 
transformation through ubquitin-dependent degradation (Kim et al., 2004). 
While c-Src activity is finely regulated, v-Src results constitutively active because it lacks this 
crucial  C-terminal  negative-regulatory  region  and  consequently  shows  higher  levels  of 
activity and transforming ability. In addition, v-src gene contains point mutations throughout 
its  coding  region  that  contribute  to  the  high  level  of  intrinsic  activity  and  transforming 
potential of the v-Src protein (Fig11.  Takeya and Hanafusa 1982;  Jove and Hanafusa 1987; 
Yeatman, 2004). 
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Figure11: Structural domains of c-Src and v-Src.  The c-Src protein is composed of an amino-terminal 
myristoylation  sequence  (M),  a  unique  region  (U),  Src-homology-2  (SH2)  and  SH3  protein-interaction 
domains, a kinase domain that contains Tyr416 and a carboxy-terminal regulatory domain (R) that contains 
Tyr527. v-Src proteins differ from c-Src in several ways, but the most important difference is the substitution 
of the negative regulatory carboxy-terminal region (modified from Frame et al., 2002).
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4.2. The v-Src transformed phenotype 
The highly activated v-Src oncogene has been revealed very useful to understand the function 
of SRC proteins. The generation of RSV mutants that were non-conditionally defective or 
temperature sensitive (ts) for transformation provided the first demonstration that a protein, v-
Src,  can  initiate  and maintain  cell  transformation  (Martin,  2001). v-Src transformation  of 
normal fibroblasts is a visible event, leading to morphological changes in transfected cells. 
Transformed cells have a loss of bundled actin filaments and a reduction in the number and 
the size of cell–substrate adhesions (focal adhesions) into which actin filaments are tethered 
(Frame  et  al.,  2002;  Yeatman,  2004).  This  results  in  conversion  from  a  well-spread 
morphology to a more refractile and fusiform cell shape, particularly in established cell lines. 
The lost of the intercellular,  integrin-based cytoskeletal  attachments could induce also the 
more extreme cell rounding and detachment from the substratum (Jove and Hanafusa, 1987). 
v-Src-transformed cells are also more motile and more able to invade the basement-membrane 
matrix. Over the course of weeks, v-Src transformation can result in overgrown clumps of 
cells, known as foci, where cells lose their density inhibition - a hallmark of a cancer cell. 
These  changes  are  consistent  with  the  processes  that  are  needed  for  a  cancer  cell  to 
disaggregate from the primary tumor, invade the surrounding tissue and metastasize to distant 
organ  sites.  In  addition  to  these  effects,  the  v-Src  oncoprotein  has  growth-promoting 
functions in fibroblasts. v-Src-transformed cells suppress the expression of p27, leading to 
more  rapid  transit  through  the  G1 phase  and a  failure  to  enter  the  quiescent  state  when 
deprived of serum mitogens (Johnson et al., 1998; Riley et al., 2001). As well as suppression 
of p27, activation of ts v-Src in quiescent cells sequentially induces expression of cyclins D1, 
E and A and activity of cyclinD1/D3-CDK4/6, cyclinE-CDK2 and cyclinA-CDK2 (Riley et 
al., 2001). These combined effects on positive and negative regulators of the cell cycle require 
the activities of the PI3K and MEK pathways downstream of v-Src and drive cells through G1 
and into S-phase (Riley et al., 2001). Recently, a direct phosphorylation of src on p27 Y74 has 
been also shown (see above).  In vivo, transfected cells grow rapidly to form visible tumors 
within days of injection, and these tumors are capable of local invasion and metastasis to 
distant sites (Yeatman, 2004).
v-Src is transported to the cell periphery, where it has a crucial function in the regulation of 
the actin cytoskeleton and cellular adhesions, even if v-Src was also reported to be present in 
the perinuclear region of transformed cells (Rohrschneider, 1979). The effects of v-Src on the 
actin  cytoskeleton  and  focal  adhesion  are  responsible  for  the  rounded  morphology  and 
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reduced  adhesiveness  of  transformed  cells.  Many  aspects  have  apparent  parallels  in  the 
biology of c-Src, which is also transported to equivalent peripheral sites where its activity is 
required for cell migration. Although such parallels can be drawn, this is not to imply that v-
Src simply reproduces an extreme and uncontrolled copy of the biological function of c-Src in 
normal  homeostasis.  Even  when  over-expressed,  c-Src  cannot  transform cells  because  its 
kinase activity is subject to tight negative regulation (Thomas and Brugge, 1997). However, 
constitutively activated c-Src can induce oncogenic transformation, which implies that v-Src 
and c-Src share at least some effectors that determine the transformed phenotype (Frame et 
al., 2002). 
4.3. Molecular mechanisms of Src functions 
The complexity of Src phenotype  is  indicative of how wide its  activity is.  As mentioned 
before, v-src shows growth-promoting effects in fibroblasts, modulating the activity of both 
positive and negative cell cycle regulators. v-Src acts also as a survival factor affecting the 
fine balance between survival and death and promoting cell cycle progression in unfavorable 
conditions such as low serum concentration, via PI3K and AKT signaling. Moreover, v-Src is 
able to overcome the normal adhesion requirement for proliferation and induces anchorage 
independent growth (Frame, 2002). 
But first of all, Src is well known to be a key regulator of cellular actin and adhesion network. 
Src is localized in the focal adhesions and assembled into supramolecular structures with over 
other 50 different cytoskeletal proteins. Focal adhesions are disassembled when the cell needs 
to move along or away from the ECM and Src contributes to this process leading to disruption 
of focal adhesions and actin stress fibers. This occurs both during normal cellular migration 
and mitosis, when cells round up and lose their matrix attachments and during transformation, 
when  the  integrity  of  these  structures  is  disrupted,  permitting  increased  motility  (Hynes, 
1992). v-Src, as c-Src, induces, a block downstream the RhoA signaling through activation of 
p190  RhoGAP,  leading  to  focal-adhesion  disruption.  Src  is  also  thought  to  affect  focal 
adhesions  by  inducing  tyrosine  phosphorylation  of  R-Ras,  by  dephosphorylation  and 
activation of the actin-severing protein cofilin and by phosphorylation and activation of FAK. 
Moreover, Src might affect migration and invasion by regulating matrix metalloproteinases 
(MMPs),  tissue  inhibitors  of  MMPs (TIMPs)  and  E-cadherin  levels  (Yeatman,  2004).  In 
particular the E-cadherin down-regulation is a key event in the carcinoma progression and 
Src, in cooperation with EGF and HGF, promotes it by stimulating the ubiquitination of E-
cadherin and leading to its endocytosis. In epithelial cancers the disruption or the weakening 
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of  epithelial  cell-cell  adhesion  facilitates  invasion  inducing  the  epithelial-mesenchymal 
transition (Fig12. Frame, 2002).
4.4. Src is altered in tumors
Despite  the accumulation of information during decades of research,  and the now refined 
molecular  understanding of how Src is  controlled,  we still  have an incomplete  picture  of 
whether, and how, misregulation of Src might contribute to the malignant phenotype. 
Among all the members of SFK family,  it is primarily Src that has been implicated in the 
development  of  human  cancer.  Like  oncogenic  v-Src,  activated  mutants  of  c-Src  can 
transform cells in culture and induce tumors in animal models (Frame, 2002). In addition, 
there  are  many reports  showing how Src protein expression and/or activity  is  elevated in 
epithelial cancers, or cell lines derived from these, and there is often an association with stage 
of disease or with malignant potential (Frame, 2002). In fact, in many cancers, increased Src 
kinase  activity  is  associated  with  advanced-stage  tumors  that  readily  metastasize  and  is 
thought to have an important role in the metastatic potential of these tumours, influencing 
directly tumour growth and cancer-cell adhesion, motility and invasion (Yeatmen, 2004).
In colon cancer, cellular Src kinase activity is frequently elevated compared to the adjacent 
normal mucosa and the activation is linked to malignant potential (Frame, 2002). Although an 
increased  Src  activity  was  also  observed  in  premalignant  lesions  and  in  adenomas,  it  is 
generally highest in malignant polyps. The reduction of Src protein expression in HT29 colon 
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Figure12:  Src  activity  promotes  the epithelial-mesenchymal  transition  and cell 
migration.  In  carcinoma  progression, Src  and  EGF/HGF  cooperate  to  induce  the 
weakening  of  cadherin-dependent  cell-cell  interactions  and  the  switch  to  a 
mesenchymal-like motility (modified from Frame, 2002)
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cancer cells using an antisense approach suppresses their growth both in vitro and in vivo. 
Further, higher Src activity is often observed in metastases compared to the corresponding 
primary tumors and activation of Src by receptor tyrosine kinases occurs in cells that have 
high metastatic potential (Frame, 2002). Taken together, current evidence implies that there is 
generally an early increase in Src activity accompanying tumour initiation and a stepwise 
increase during the progression of colon cancer. 
There is also circumstantial evidence that Src activity might be playing a role in breast and 
other epithelial cancers. For example, Src is over-expressed or shows an elevated activity in 
breast carcinomas compared to normal tissue, in breast cancer cells lines and in mouse models 
of mammary tumours (Frame, 2002). Src is also frequently up-regulated in pancreatic cancers 
and cell lines derived from these, as well as in ovarian, esophageal, lung, head and neck and 
gastric cancers (Frame, 2002). 
Src  expression  and  activity  are  increased  also  in  melanoma  cell  lines  and  in  melanoma 
tumors.  In melanoma,  Src can activate STAT3, STAT5 and other downstream targets and 
their  activated  forms  are  present  in  both  primary  and  metastatic  melanoma  in  humans, 
although the expression level is variable (Frame, 2002).
All these observation strongly suggests that  the elevated expression and/or activity of Src 
facilitate malignant progression. However, the way in which Src activation is stimulated and 
how this contributes to the cancer phenotype, are still not completely defined.
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In  cancer,  the  uncontrolled  cell  proliferation  and  the  ability  to  invade  tissues  and  form 
metastasis,  are  two of  the  most  important  features.  Thus,  the  understanding  of  molecular 
mechanisms that regulate the cell growth and the motility behaviour becomes crucial for the 
development of new anticancer therapies.
Among all  the molecular  effectors that  could have a role in tumor progression,  particular 
interest has received the inhibitor of cyclin-CDK complexes p27kip1 (p27). p27 represents an 
ideal target displaying on one hand an inhibitory effect in cell cycle progression and on the 
other hand by regulating cell motility, as recently demonstrated by different authors.
In  this  PhD project  we aimed  to  clarify  whether  and how p27 contributes  to  the  proper 
coordination  of  proliferation  and  motility  in  the  process  of  neoplastic  transformation.  In 
particular, we decided to evaluate if the presence or absence of p27 could be associated to 
different responses after oncogenic stimuli. We used murine immortalized fibroblasts, derived 
from embryos wild type or knock out for the cdkn1b gene, encoding for the p27 protein, and 
then transformed by over-expression of v-src oncogene. The Harvey-Ras oncogene was used 
in the same manner to highlight common responses or different “oncogene-specific” effects. 
The selected cell clones were then analysed with several  in vitro and in vivo  experimental 
approaches in order to characterize both their proliferative and motile behaviour and to gain 
new information about p27 functions in the first steps of neoplastic transformation as well as 
in the later stages of  tumor progression. 
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MATERIALS AND METHODS
1. Cell cultures and development of stable cell lines.
3T3 p27 wt and null fibroblasts were kindly provided by Dr. M. Fero. All described cell lines 
were  grown  in  DMEM  (Dulbecco's  Modified  Eagle's  Medium,  Cambrex  Bio  Science) 
supplemented with 10% FBS (Sigma). To obtain stable cell clones, pM-vSrc (Johnson et al., 
1985) was co-transfected with pTRE2pur (Clontech) or pMSCV-Hyg (Clontech), using the 
calcium phosphate procedure or FuGENE6® (3,5µl of FuGENE6®  / µg of DNA). pMSCV-
HRAS and all the p27 expressing vectors were retrovirally transduced. 
Retroviral transduction was performed by transfecting the pMSCV vectors together with the 
pHIT60 vector, containing the gag-pro-pol genes and the pHIT123, containing the env gene 
for mouse tropism, into the HEK-293 cells, using the calcium phosphate procedure. Three 
days later, conditioned medium harvested from 3 dishes (containing retroviruses) was used to 
transduce one  dish of exponentially growing 3T3 p27wt or null fibroblasts. Clones and pools 
were selected in complete medium with 1,5µg/ml Puromycin and/or 0,4mg/ml Hygromycin. 
The stable expression of the different constructs was tested by western blot analysis.
2. Cell culture in 3D collagen lattices.
3D  collagen  matrix  was  prepared  using  both  native  dermal  bovine  (Vitrogen;  PURE-
COL/Nutacon)  or  rat  tail  (BD)  collagen  type  I  (Wolf  et  al.,  2003).  In  this  study  both 
individual cells and multicellular spheroids were used. Spheroids were obtained seeding cells 
onto not-adhesive bacterial petri dish or in polyHEMA-coated dish, collecting the obtained 
cell clumps 24hours after plating. Then, spheroids or single cells from subconfluent cultures 
(detached  with  2mM  EDTA)  were  included  into  the  collagen  mix  (1.7  mg/ml)  at 
physiological pH. The suspension was allowed to polymerize for 45 minutes at 37°C in a 5% 
CO2 atmosphere, in a self-constructed chamber (Friedl et al., 1993). After polymerization of 
the collagen lattice,  FBS-containing medium (10% final FBS concentration) was added as 
supernatant and the chamber was sealed. 
3. Time-lapse microscopy and quantification of cell migration.
Individual  cells  or  multicellular  spheroids  incorporated  within  3D collagen matrices  were 
monitored by digital bright-field microscopy in order to discriminate cells along the different 
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axes.  The  pictures  were  collected  every  4  or  5  min  for  20  hours,  using  a  CCD camera 
mounted  onto  the  microscope.  A  10X  (for  speed  analysis)  or  20X  (for  morphological 
analysis) objectives were used. The cells were maintained at 37°C during all the recording 
time using  a  remote  temperature  control  system and a  heating  device.  At  the  end of  the 
recording, pictures were used to create a movie (10 images per second, Quicktime), and used 
for  cell  tracking  analysis.  After  conversion  of  pixel  values  into  micrometers,  single  cell 
migration was quantified by computer-assisted cell tracking of at least 40 randomly selected 
cells for each experiment, obtaining several locomotion parameters, such as velocity, speed 
and paths. 
Velocity describes the actual  translocation efficiency of cells  in the process of migration, 
delineating the “true” speed without interference of stopping frequencies. Speed represents a 
more general parameter describing overall motility as a function of the fraction of locomoting 
cells  and their  locomotor  duration,  individual  step lengths and step number.  Using the  xy 
coordinates of cell paths, the speed and velocity were calculated as the length of each cell path 
divided by time (step interval, 12 minutes). Statistical analysis was obtained from the two-
tailed unpaired Student's t-test or the two-tailed unpaired Mann-Whitney test.
4. Transwell-based migration assay. 
Cell lines were tested for invasion and motility by fluorescence-assisted transmigration assay 
(FATIMA, Spessotto et al., 2000), in response to haptotactic stimuli of ECM substrates. The 
procedure is based on the use of transwell-like inserts (HTS FluoroBlok™, Becton-Dickinson, 
Falcon, Milan, Italy) carrying fluorescence shielding porous polyethylene terephthalate (PET) 
membranes with 8μm pores.
For haptotaxis, bottom side of HTS Fluoroblok™ were coated with 20µg/ml fibronectin in 
carbonate buffer at 4°C overnight and then saturated with PBS 1% BSA for 2 hours at room 
temperature. Cells were labeled with DiI (Molecular Probes) for 20 minutes at 37°C before 
being seeded on the Fluoroblok™ upper chamber and then incubated at 37°C for the indicated 
times. 
Migratory  behavior  of  the  cells  was  monitored  at  different  time-points  by  detection  of 
fluorescence  from  the  top  (corresponding  to  non-migrated  cells)  and  the  bottom 
(corresponding  to  migrated  cells)  sides  of  the  membrane  using  the  computer-interfaced 
GENios  Plus  (TECAN  Italia  Srl).  Each  experiment  was  performed  at  least  3  times,  in 
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duplicate.  As a further control,  after the last measurement,  Fluoroblok™ membranes were 
fixed in 4% PFA and mounted on a slide, to allow the manual count of migrated cells. 
5. Matrigel™  and Collagen I evasion assay.
For  3D  Matrigel™  and  Collagen  I  evasion  assay,  cells  (7,5x105/ml)  were  included  in 
Matrigel™ (6 mg/ml,  Becton Dickinson) or in Collagen I  (1,7 mg/ml,  Becton Dickinson) 
drops and maintained 1 hr up side down to polymerize at 37°C. Collagen I was diluted in a 
mix  solution  containing  DMEM-10X  (w/o  phenol  red),  7,5%  sodium  bicarbonate  and 
complete medium. Then drops were incubated for the indicated times in complete medium. 
Cell motility was observed by transmission microscopy using a Nikon TS100/F microscope 
and images collected using a CCD camera (Leica). Cells outside each drop (five drops/cell 
line/experiment) were counted to estimate the cell line evasion ability.
The evasion ability was also estimated by measuring the distance covered by the cells from 
the drop edges, after 5 days from inclusion. To perform this analysis, cells were stained with 
crystal violet and then pictures were taken. After conversion from pixel to millimeters, the 
actual distance covered was calculated.
6. Cell adhesion assay.
The quantitative cell adhesion assay used in this study has been previously described (using 
centrifugal  assay  for  fluorescence-based  cell  adhesion-CAFCA;  Giacomello  et  al.,  1999; 
Spessotto  et  al.,  2000).  Briefly,  six-well  strips  miniplates  (of  flexible  polyvinyl  chloride), 
covered  with  double-sided  tape  (bottom units),  were  coated  with  the  different  substrates 
(20µg/ml  Collagen  I,  10  µg/ml  Vitronectin  and  10µg/ml  Fibronectin.  BSA  was  used  as 
negative control).  Cells  were labeled with the vital  fluorochrome Calcein AM (Molecular 
Probes) for 15 minutes at 37°C and then dispensed into the bottom CAFCA miniplates, which 
were  then  centrifuged  to  synchronize  the  contact  of  the  cells  with  the  substrate.  The 
miniplates  were  then  incubated  for  20  minutes  at  37°C and  then  mounted  together  with 
another  CAFCA  miniplate  to  create  communicating  chambers  for  subsequent  reverse 
centrifugation. The relative number of cells bound to the substrate (i.e. remaining in the wells 
of the bottom miniplates) and cells that fail to bind to the substrate (i.e. remaining in the wells 
of the top miniplates)  was estimated by top/bottom fluorescence detection in a computer-
interfaced GENios Plus microplate fluorometer (TECAN Italia S.r.L., Milan, Italy). 
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The analysis  of signal  transduction  pathways  activated  after  cell  adhesion was performed 
seeding about 1x106 cells in 100mm dishes, coated with 20µg/ml collagen I. At the indicated 
time points (15, 30, 60 minutes), cells were collected and total protein extracts were obtained 
as described below (point 7).
7. Preparation of cell lysates, immunoprecipitation and immunoblotting.
Total cell proteins were extracted using cold NP40 lysis buffer (0,5% NP40; 50mM HEPES 
pH7;  250mM  NaCl;  5mM  EDTA;  0,5mM  EGTA  pH8)  containing  a  protease  inhibitor 
cocktail (Complete™, Roche), 1mM sodium orthovanadate and 1mM DTT. After incubation 
on ice for 30 min, the lysates were centrifuged at max speed for 10 min at 4°C to recover the 
supernatant.
Immunoprecipitation experiments were performed using 0.5mg of total lysate, adding HNTG 
buffer (20mM HEPES, 150mM NaCl, 10%Glycerol,  0.1%Triton X-100, protease inhibitor 
cocktail,  1mM sodium orthovanadate and 1mM DTT) with the specific agarose-conjugated 
primary  antibodies,  gently  rocking  overnight  at  4°C.  When  primary  antibodies  were  not 
agarose-conjugated, Protein A or Protein G Sepharose 4 Fast Flow (Amersham Biosciences), 
was added for the last 2 hr of incubation. Immunoprecipitates were then washed six times in 
HNTG buffer and then nine parts were resuspended in 3X Laemli Sample Buffer (50mM 
TrisHCl pH6,8, 2% SDS, 10% glycerol, 0,5% Bromophenol Blue, with fresh 50mM DTT) for 
immunoblot analysis and one part was resuspended in kinase buffer (20mM TrisHCl pH6.8, 
10mM MgCl2) to perform a kinase assays (see the following chapter). 
For immunoblot analysis,  proteins were separated in 4-20% SDS-PAGE (Criterion Precast 
Gel,  Biorad)  and  transferred  to  nitrocellulose  membranes  (Amersham).  Membranes  were 
blocked with 5% dried  milk  in  TBS-0,1% Tween or  in  Odyssey Blocking Buffer  (Licor, 
Biosciences) and incubated at 4°C overnight with primary antibodies. 
Primary  antibodies  were  from:  Transduction  Laboratories  (p27,  CDK1,  CDK2,  FAK, 
Cofilin),  Santa  Cruz  (CDK1,  CDK2-AC,  Cyclin  B1,  Cyclin  A,  vinculin,  c-Src,  H-Ras, 
pY705-Stat3, Stat3, Akt), Cell Signaling (pS473-Akt, pT202/Y204-p42/44-MAPK, p42/44-
MAPK, pS3-Cofilin), Biosource (pY397-Fak, pS473-Akt). 
Then,  membranes  were  washed,  incubated  1  hour  at  room temperature  with  horseradish 
peroxidase (HRP)-conjugated secondary antibodies, for chemi-luminescent  detection  (ECL 
Kit,  Amersham Inc.)  or with  Alexa-conjugated secondary antibodies for infrared detection 
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(Odyssey Infrared Detection System, Licor). For immunoprecipitates, Rabbit IgG and Mouse 
IgG True Blot (eBioscience) secondary HRP-conjugated antibodies were used. 
The Restore™ Western Blot Stripping Solution (Pierce) was used to strip the membranes, 
when re-blotting was needed.
8. Growth curve, MTT assay and FACS analysis.
Cell proliferation was evaluated using growth curves, MTT assay and FACS analysis after 
Propidium Iodide labeling. For MTT assay (Sigma), 1000 cells/well were seeded in 96 well 
plates.  At  the  indicated  times,  MTT  solution (3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium  bromide,  a  tetrazole) in  complete  medium  (0,28mg/ml  final 
concentration) was added and incubated at 37°C for 4 hours. During this incubation, MTT is 
reduced to purple formazan in the mitochondria of living cells. The medium was then discard 
and the formazan salts were dissolved in DMSO. The colorimetric reaction was measured and 
quantified at 560 nm in Elisa plate reader. 
For  cell  growth,  1x105 cells/well  were  seeded  in  6  well  plates  in  complete  medium  in 
duplicate. At the indicated time, cells were detached in trypsin-EDTA and counted. 
Cell cycle distribution was analyzed by FACS analysis. Cells were collected and fixed in ice-
cold 70% ethanol and maintained at -20°C until ready for the staining procedure. Cells were 
then  washed  and  resuspended  in  propidium iodide  staining  solution  (50µg/ml  propidium 
iodide and 0,1mg/ml RNaseA, in PBS 1X). Stained cells were subjected to flow cytometry 
analysis (FACS) with a FACScan and a FACSCalibur instrument (BD Biosciences). The data 
were analysed using WinMDI2.8 software.
9. Kinase assay.
After immunoprecipitation with anti-CDK1, -CDK2, -CyclinA or -CyclinB1 antibodies,  or 
with the control antibodies, the associated kinase activity was evaluated, as follows. Samples 
were mixed with a kinase reaction solution containing 50µM not labelled ATP + γATP-P32 
and  2µg  of  H1-Histon  as  substrate  in  buffered  solution  (20mM  TrisHCl  pH6.8,  10mM 
MgCl2). The reaction was carried out at 30°C for 30 min and then 2X Laemli Sample Buffer 
was added. After denaturation at 95°C for 5 min,  proteins were loaded on a 4-20% SDS-
PAGE  (Criterion  Precast  Gel,  Biorad).  The  gel  was  then  dried  and  exposed  on  an 
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autoradiographic film (Amersham-Hyperfilm MP) at -80°C and developed after different time 
intervals.
10. Double thymidine block and nocodazole assay.
The double thymidine block was used to synchronize the cell cycle progression. Thymidine is 
a deoxynucleoside able to inhibit DNA replication if added in excess in the medium, inducing 
a reversible block at the G1/S transition. We performed a first treatment with 2mM thymidine 
for  15-16  hours  in  cells  plated  at  about  20-30% of  confluence.  At  the  end  of  the  first 
incubation, the cells were detached and seeded again at 30% of confluence and released in 
complete  medium  (DMEM-10%FBS)  for  8  hours.  Then  a  second  thymidine  block  was 
performed (12 hours with 2mM thymidine in complete medium) at the end of which most of 
the cells resulted blocked at the beginning of S-phase. At this point, cells were released in 
complete  medium  for  6  hours  and  then  incubated  5  hours  with  50ng/ml  nocodazole. 
Nocodazole is a MT destabilizing drug that inhibits the assembling of the mitotic spindle and 
blocks the cells at the beginning of M phase (in pro-metaphase). To analyse the progression 
along the mitosis, cells were collected at T0 (i.e. in pro-metaphase) and after 30, 60, 90, 120 
and 180 minutes of release in complete medium and analyzed by FACS.
11. Anchorage-independent cell growth
To evaluate the cell ability to grow in an anchorage independent manner, soft agar assay was 
performed.  Cells  (1  ×  103 and  5  ×  103)  were  suspended  in  2ml  TOP  agar  medium 
(DMEM-10%FBS containing 0.4% Low Melting Agarose-SIGMA). The cell suspension was 
then layered on 2ml of jellified BOTTOM agar medium (DMEM-10%FBS containing 0.6% 
Low Melting Agarose) in six-well tissue culture plates in triplicate. DMEM-10%FBS with 
1,5µg/ml Puromycin  and/or 0,4mg/ml  Hygromycin  (depending from the selection needed) 
was added to the plates every 3 days, as a feeder layer. On day 8 for Src clones and day 12 for 
Ras  clones,  the  number  of  colonies  was  counted  in  15  randomly  selected  fields,  at  10X 
magnification.
12. In vivo analysis
Primary tumors  were established  by  s.c. injection  of   transformed  cells  into the  flank  of 
female athymic nude mice (Harlan, 8 weeks of age). 1x106 v-src transformed cells and 2 x106 
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H-Ras  transformed  cells  were  injected.  The  tumor  growth  was  followed every  other  day 
measuring the mass with a calibre. 15 days from injection in the case of v-src transformed cell 
and 22 days in the case of H-Ras cells, the animals were sacrificed and tumor analysis was 
performed.  To  analyze  the  invasive  potential,  spleen,  lung  and  blood  samples  were  also 
collected and rapidly frozen to preserve RNA integrity. 
In a second type of experiment we tried to evaluate the ability of the transformed cells to 
settle and colonize distant sites. To this aim, 1x106 cells have been injected into the tail vein. 
After about 20 days, the animals were sacrificed and lungs were fixed in Bouin’s solution to 
look for foci formation. 
13. RNA extraction and RT-PCR from tissue samples
Isolation of RNA from spleen, lung and blood samples was performed using RNeasy-Mini Kit 
(QIAGEN), according to the manufacture’s instructions. Disruption of the tissue sample was 
achieved by grinding the frozen tissue thoroughly with lead blocks. The homogenization was 
performed passing the lysate at least 5 times through a blunt 23-gauge needle fitted to an 
RNase-free syringe. 
RNA were then quantified and retro-transcribed with AMV Reverse transcriptase (according 
to provider’s instruction, Promega) and the obtained cDNAs were amplified with nested PCR, 
in order to evaluate the presence of ectopic injected cells in tissue samples. 
The following primers were used: 
pTREforward1 5’-CAGCAGGCAGAAGTATGCAA-3’, 
pTREforward2 5’-TGCAAAGCATGCATCTCAAT-3’, 
pTREreverse1 5’-CGTGAGGAAGAGTTCTTGCAG-3’, 
pTREreverse2 5’-AGTTCTTGCAGCTCGGTGAC-3’, 
pMSCVforward 5’-CCCTTGAACCTCCTCGTTCGACC-3’, 
pMSCVreverse  5’-GAGACGTGCTACTTCCATTTGTC-3’, 
H-RASforward 5’-GGATCCATGACGGAATATAAG-3’
H-RASreverse 5’-GAATTCTCAGGAGAGCACACA-3’ 
p27-170reverse 5’-GGATCCCTCGAGTGTTCTGTTGGCTCTTTT-3’.
Samples were normalized by amplification of 18S ribosomal subunit. PCR products were then 
resolved on 1% agarose gels stained with ethidium bromide.
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14. Immunofluorescence Analysis
For immunofluorescence staining, cells included in Matrigel™ or collagen I drops were fixed 
in PBS 4% paraformaldehyde (PFA) at room temperature (RT), permeabilized in PBS 0.2% 
Triton X-100 and blocked in PBS 1% BSA and 10% normal goat serum for at least 2 hours. 
Incubation  with  FITC-conjugated  monoclonal  anti-α-tubulin  antibody  (SIGMA)  and 
Phallotoxin-AlexaFluor546 (Molecular probes-Invitrogen) for actin detection was performed 
at RT for two hours in PBS 1% BSA and 1% normal goat serum. Cover slips were mounted in 
Mowiol  4–88  (Calbiochem-Novabiochem)  containing  2.5%  (w/v)  DABCO  (Sigma).  To 
visualize collagen fibers, laser light at a low density (the “reflection” parameter in confocal 
microscopy) was used and the light reflected by the sample was detected, allowing a sensitive 
recognition of fibers. Images were acquired with a Leica TCS SP2 confocal system (Leica 
Microsystems Heidelberg, Mannheim, Germany), using the Leica Confocal Software (LCS). 
15. Statistical analysis
Statistical  significance  of  the  results  was  determined  by  using  the  paired  and  unpaired 
Student’s t-test. A p value <0.01 was considered significant.
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RESULTS
1. p27-/- v-src transformed cells exhibit higher proliferation potential than p27+/+ cells
To gain new information on the role of p27 in cell transformation, the oncogene v-src was 
used  to  transform  mouse  fibroblasts  derived  from  p27+/+ and  p27-/- genetic  background. 
Fibroblasts  have  been  previously  immortalized  by  3T3  protocol  (kindly  provided  by  Dr. 
Fero). Two independent cell clones stably over-expressing comparable levels of v-src for each 
genotype (Fig. 1) were fully characterized.
The v-src transformation process is known to promote cell growth by altering the levels of 
both positive and negative cell cycle regulators and, among all, p27 results down-regulated 
after v-src over-expression (Johnson et al., 1998; Riley et al., 2001). In agreement with the 
literature data, we observed a decrease in the amount of endogenous p27 after transformation, 
but the relative low p27 levels were then retained throughout the time and confirmed after 
each experiments (Fig. 1). 
Being p27 a well known tumor suppressor gene able to inhibit cell proliferation, the selected 
clones were initially analyzed for their proliferative behavior. First, cell  distribution in the 
different phases of the cell  cycle  was evaluated by FACS analysis  of DNA content. This 
analysis demonstrated that  v-src p27-/-  fibroblasts had a sensible higher S phase population 
respect to the wild type counterpart (38,4% for p27ko versus 25,4% for p27wt cells. Fig. 2A), 
suggesting  that  p27 absence  increased v-src  cell  proliferation  rate.  Accordingly,  both cell 
growth  curve  and  MTT  proliferation  assays  demonstrated  that  p27KO v-src  cells  grown 
significantly better than the p27WT transformed cell clone (Fig. 2B, C). 
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Figure 1: Clones selection. Expression of v-src 
and p27 protein in 3T3p27wt and ko cell clones. 
Vinculin expression was  used to  normalize the 
amount of loaded proteins.
Results
It  is  well  accepted  that  p27 regulates  cell  cycle  progression by interacting  and inhibiting 
different cyclin-CDK complexes but with higher sensibility the CDK2 and CDK1 containing 
complexes (Belletti et al., 2005).  To evaluate if the growth differences previously observed 
(Fig.  2)  could be ascribed to  a  different  CDKs activity,  we performed a kinase assay in 
proliferating cells. As expected, the activity of CDK1 and CDK2 was significantly higher in 
p27KO than in p27WT v-src cells, although with some experimental variability (Fig. 3A, B). 
These results were then confirmed by assaying the cyclin A and B1 associated kinase activity 
(Fig.  3C,  D),  thus  obtaining  a  molecular  explanation  for  the  different  proliferation  rate 
observed.
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Figure 2: Proliferative behaviour of v-src transformed cell clones. A. Cell cycle distribution of p27WT and 
KO v-src cells was evaluated in exponentially growing cells by FACS analysis after PI staining of the DNA. 
The percentages of the cells in each phase is reported in the graph. A typical experiment is shown. B. Growth 
curve analysis of v-src transformed fibroblasts. 1x 105 cells/well were plated in triplicate and counted each day 
for 4 days.  C. MTT assay in which 1x103 cells/well were seeded in sixth-plicate in 96well plates. Cells were 
harvested  every  24  hours  and  cell  proliferation  quantified  at  560nm in  Elisa  plate  reader  as  described  in 
materials and methods section.   
Figure 3:  CDKs  and  cyclins-
associated kinase activity in v-src 
transformed  fibroblasts.  After 
immunoprecipitation  for  CDK1 
(A), CDK2 (B), CyclinB1 (C) and 
CyclinA (D), the associated kinase 
activity  was  evaluated  using  a 
radioactive  kinase  assay  in  which 
the  Histon  H1  was  used  as 
substrate.  A  typical  experiment  is 
shown.
Results
It is well known that p27 is a major regulator of the G1-S phase transition. To specifically 
analyze its contribution in this phase of the cell cycle in v-src transformed cells, we tried to 
synchronize the cells in the G1 phase by serum starvation and then re-stimulating cell cycle 
enter by release in complete medium. As control,  normal p27+/+ and p27-/- 3T3 fibroblasts 
were used. After 24 hours of serum starvation, both p27WT and p27KO normal cells arrested in 
G1 phase and re-entered in S phase after about 15 hours of serum stimulation (Fig. 4A). This 
result was then confirmed by western blot analysis of typical markers of S (cyclin A) or G2-M 
(cyclin B1) phases of the cell cycle (Fig. 4B) in which we observed an increase in cyclin A 
levels after about 15 hours and of cyclin B1 after 21 hours from serum stimulation.
Differently by normal cells, transformed v-src fibroblasts were less sensitive to growth factor 
deprivation (Fig. 5). However both FACS analysis of DNA content (Fig. 5A) and western blot 
(Fig. 5B), demonstrated that p27+/+ v-src cells are more sensitive to serum deprivation than 
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Figure  4:  Serum  dependent  cell  cycle  entry  of  normal  p27wt  and  null 
fibroblasts. A. FACS analysis of 3T3 fibroblasts serum starved for 24 hours (T0) 
and then released in complete medium for 9, 15 and 21 hours. B. The cells treated 
as in A were analyzed by western blot for the expression of the indicated proteins. 
Vinculin expression was used as loading control. A typical experiment is shown.
Results
p27 null cells. In fact, a transient reduction of S phase population and of cyclin A and B1 
expression was seen in normal but not in p27 null v-src cells.
Interestingly, FACS analysis of transformed cells grown to confluence (Fig. 6) demonstrated 
that  p27  expression  is  important  to  induce  cell  cycle  arrest  after  cell-cell  contact  in 
transformed but not in normal fibroblasts. In fact while normal fibroblasts, independently on 
their genotype arrest in G1 after cell-cell contact, v-src transformed cells respond to contact 
inhibition only when p27 is present.
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Figure 5: Serum dependent cell cycle entry of v-src transformed p27wt 
and null fibroblasts. A. FACS analysis of v-src cell clones serum starved for 
24 hours (T0) and then released in complete medium for 9, 15 and 21 hours. B.
The cells treated as in A  were analyzed by western blot for the expression of 
the indicated proteins. Vinculin expression was used as loading control. A 
typical experiment is shown
Results
Overall these data demonstrated that p27 plays an important role in the control of cell cycle 
progression of v-src transformed fibroblasts and that, in these cells, it has a major function in 
the transition between G1 and S phase.
We next analyzed whether v-src fibroblasts were effectively transformed and tumorigenic and 
if p27 had any effects on the process of transformation.  A typical hallmark of transformed 
fibroblasts  is  the  ability  to  grow in an  anchorage  independent  way and in  several  model 
systems v-src has been proved to be able to confer this ability (Pawlak and Helfman, 2001). 
Thus, as a first approach, p27+/+ and p27-/- v-src cells were assayed in a soft agar assay and, as 
expected,  both resulted able to grow in an anchorage independent way. However, p27 null 
cells  displayed a significant  increase in the number and the size of formed colonies (Fig. 
7A,B), a result that is in line with the 2D proliferation assays. 
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Figure 6: Proliferative behaviour of cells grown to confluence.  Normal and v-src transformed 
cells were grown to confluence and then analysed by FACS. A typical experiment in which two 
different  cell  clones/genotype  have  been analyzed  is  shown.  The distribution of  the cells  in  the 
different phases of the cell cycle is reported in each histogram.
Figure 7: Characterization of anchorage-independent growth.  v-src transformed cells were tested in 
soft agar assay in triplicate (0,4% TOP, 0,6% BOTTOM of agar concentration). After 8 days, colonies 
were counted (A) and representative pictures (B) were collected. 10X objective was used and for each cell 
lines 15 fields were counted. (Student’s t test: p27wt vs p27ko: p<0,001).
Results
Next, two different clones of p27+/+ and p27-/- v-src fibroblasts were subcutaneously injected 
in nude mice (n=19 for p27+/+ and n=15 for p27-/- v-src cells). Xenografts were followed for 
about 15 days and then the mice were sacrificed and the tumor masses analyzed. Data showed 
that tumors formed from p27-/- transformed cells were significantly bigger in size (Fig. 8A, B) 
and  weight  (Fig.  8C)  than  the  wild  type  counterpart,  indicating  that  also  in  vivo p27 
expression could influence the proliferative behavior of transformed cells. 
Importantly, no significant variations were observed between the two wild type and the two 
knock out cell clones utilized (Fig. 8D), demonstrating that the differences observed between 
p27+/+ and p27-/- v-src fibroblasts were not due to clonal selection.
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Figure 8: In vivo growth of v-src transformed cells. 1x106 cells were injected subcutaneously in the flank 
of nude mice and mice have been sacrificed 15 days after. In A and B representative picture of the injected 
mice (A) and explanted tumors (B) are shown.  C. The graph displays  the tumor weight.  The differences 
between  p27wt and p27ko v-src cells are highly significant (p<1x10-5). D. The average tumor weight for each 
cell  clones  is  reported.  Whereas  the differences  among the two p27wt or  the two p27ko clones  are  not 
statistically significant, T test results significant (p≤0,006) for all the other compared couples (p27wt#A4 vs 
p27ko#3, p27wt#A4 vs p27ko#11, p27wt#A6 vs p27ko#3, p27wt#A6 vs p27ko#11).
Results
2. p27 expression discriminates between mesenchymal and amoeboid morph-dynamics.
Recently,  the  role  of  p27  in  cell  motility  has  become  a  debated  issue  in  the  scientific 
literature.  We  previously  demonstrated  a  reduction  in  3D  cell  migration  due  to  the  p27 
cytoplasmic  expression  (Baldassarre  et  al.,  2005).  Moreover,  we  also  observed  different 
morphological  features  in  cells  expressing  or  not  expressing  p27  included  in  a  3D 
environment (Belletti  et al.  in preparation and personal observations). We thus speculated 
that  p27  could  be  involved  in  the  regulation  of  cell  morph-dynamics  during  oncogenic 
transformation. To test this hypothesis, p27+/+ and p27-/- v-src fibroblasts were included in 3D 
collagen matrices and studied by time-lapse microscopy and immunofluorescence analyses. 
Their morphology was first evaluated at different time points by transmission microscopy in 
bright field to better discriminate the cell distribution along the three axes (Fig. 9A). v-src 
transformed fibroblasts included in 3D matrices acquired typically two different shapes: an 
elongated fibroblast-like spindle shape, with finger-like protrusion at the cellular edges or a 
rounded amoeboid-like morphology, characterized by numerous peripheral membrane ruffles. 
Counting the rounded versus the elongated cells after 10 hours from inclusion, we verified 
that while p27WT fibroblasts displayed a similar percentage of elongated and rounded cells 
(47,8  and  52,2±7,01%  of  elongated  and  rounded,  respectively),  p27KO v-src  fibroblasts 
acquired  an  almost  exclusively  rounded  morphology  (14%  and  86±3,3%  elongated  and 
rounded, respectively. Fig 9B). 
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Figure 9:  Morphologic 
characterization  of  v-src 
transformed  cells.  A. 
Representative  pictures  of  typical 
morphology acquired by p27wt and 
p27ko transformed fibroblasts after 
10  hours  of  inclusion  in  3D 
collagen  I  matrix.  The  pictures 
were collected in bright field using 
the 10X objective. B. Percentage of 
cells  characterized  by  the  two 
different  morphology  (the 
elongated  spindle  shape  and  the 
rounded  amoeboid-like 
morphology).  The  results  were 
obtained counting 5 fields for each 
independent  experiment.  The dead 
cells were excluded by the count.
Results
We  also  evaluated  the  cytoskeletric  structures  of  transformed  cells  in  3D  using 
immunofluorescence  and confocal  microscopy analysis.  p27WT and p27KO v-src  fibroblasts 
were cultured for 10 hours in collagen matrix and then fixed and stained for tubulin (green) 
and actin  (red)  (Fig.  10).  The analysis  highlighted  the  structural  differences  between cell 
expressing or not expressing p27. Most of transformed p27+/+ cells retained a fibroblast-like 
elongated morphology with cellular protrusions supported both by the microtubule network 
and actin stress fibers. Conversely, p27-/- v-src cells mainly displayed a rounded shape, lose 
the dendritic-like extensions and showed an actin cortical distribution and a lower content of 
microtubule (Fig. 10). 
     
 
The  same  morphological  differences  were  observed  also  performing  time  lapse  video 
microscopy of spheroids included in 3D collagen matrix. 
Spheroids  are  cell  clusters  obtained  by  seeding  cells  in  not-adhesive  Petri  dish  or  in 
polyHEMA-coated plates, thus favouring the cell-cell contacts and in turn the formation of 
cellular  clumps.  After 24 hours spheroids are collected  and included in a 3D matrices  to 
evaluate the 3D cell  morphology and motility in a different  condition than individual  cell 
inclusion. 
As shown in the photogram at 3, 6 and 9 hours from inclusion and in the movies resulting 
from the collection of pictures taken every 4 minutes for at least 12 hours, p27-/- v-src cells 
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Figure 10: Cytosckeletric structures in v-src transformed cells in 3D matrix. Cells 
included in 3D collagen I matrix were evaluated after 10 hours of inclusion for their 
actin and tubulin cytoskeleton. The actin network was stained with Phallotoxin-
AlexaFluor546 (RED), whereas for tubulin detection FITC-conjugated monoclonal anti-
α-tubulin antibody (GREEN) was used. In grey the collagen fibers are represented 
(using reflection parameter in confocal microscopy). 
Results
detached by the cell cluster retaining a rounded cell shape and showing a higher deformability 
(Fig. 11 and supplementary movie). They were able to squeeze through the collagen lattices, 
moving in a propulsive way all around with a reduced directional persistence. Conversely, 
p27+/+ transformed fibroblasts moved outside the cluster using long protrusions to generate the 
traction forces needed for the cell body advancing (Fig. 11 and supplementary movie). All 
these  features  well  fit  with  the  described  model  for  the  amoeboid  and the  mesenchymal 
morph-dynamics, respectively (Friedl and Wolf, 2003). Thus, our results demonstrate that p27 
control  the  shape  and  the  type  of  motility  during  v-src  transformation  process,  since  its 
absence favors the acquirement of an amoeboid motility.
3. The amoeboid motility of p27-/- v-src cells  is associated with higher cell  speed and 
invasive ability.
To  evaluate  if  the  two  diverse  cell  shapes  observed  in  p27  wt  and  null  cells  could  be 
associated to a different migration rate in vitro, we performed a time lapse video microscopy 
and cell tracking analysis of individual cells included in 3D collagen matrices (Fig. 12 and 
supplementary movies). We analysed the tracking parameters of 40 individual cells in two 
independent experiments. Moreover, we evaluated both the cell speed (that describes overall 
motility  as  a  function  of  the  fraction  of  locomoting  cells  and  their  locomotors  duration, 
individual  step  lengths  and  step  number)  and  cell  velocity  (that  describes  the  actual 
translocation efficiency of cells in the process of migration, without considering the stopping 
frequencies). Analysing both these parameters, p27-/- v-src cells displayed a higher migration 
rate than p27+/+  transformed cells, with a speed value of 0,227µm/min versus 0,118 µm/min 
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Figure 11: Spheroid assay of transformed cells in 3D collagen matrix.  Spheroids obtained by seeding 
cells  in  polyHEMA-coated  plates  were  included  in  3D collagen  matrix  and  evaluated  in  bright  field 
collecting one picture every 4 minutes for at least 12 hours. Here, photogram collected after 3, 6 and 9 
hours are reported.  
Results
and  a  velocity  of  0,33µm/min  versus 0,22µm/min.  (Fig.  12A,  B,  C).  In  both  cases  the 
differences between the two cell lines resulted highly significant (p<0,0001), demonstrating 
that p27 expression is an important determinant in the control of 3D locomotion. 
A
Cell speed
0
0,05
0,1
0,15
0,2
0,25
0,3
0,35
0,4
0,45
1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39
Cells
sp
ee
d 
( m
m
/m
in
)
p27wt v-src (exp1)
p27ko v-src (exp1)
p27wt v-src (exp2)
p27ko v-src (exp2)
B
Cell velocity
0
0,1
0,2
0,3
0,4
0,5
0,6
1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39
Cells
ve
lo
ci
ty
 (
m
m
/m
in
)
p27wt v-src (exp1)
p27ko v-src (exp1)
p27wt v-src (exp2)
p27ko v-src (exp2)
- 52 -
Figure 12: Locomotion parameters of 3D motility. After time lapse video microscopy of p27wt and p27ko v-
src fibroblasts included in 3D collagen matrix, the analysis of cell speed (A) and velocity (B) was performed 
using a semi-automatic cell tracking software. Two independent experiments were performed and 40 cells for 
each cell lines were tracked in each experiment. The obtained data result highly significant (p<0,0001) both in 
cell speed and in cell velocity analysis (C). The cells were followed for 20 hours collecting one picture every 5 
minutes. The step interval for tracking analysis corresponds to 12 minutes. 
Results
The different mobility is well represented also by the assumed cell trajectories that described 
how p27KO transformed cells were able to cover longer paths compared to wild type in the 
same time frame (Fig. 13). 
Moreover, cell migration was assessed by an evasion assay using both Matrigel and collagen I 
matrices. In agreement with the tracking data, the obtained results showed that p27-/- v-src 
cells displayed a higher ability than p27+/+ to migrate outside the drops, confirming again that 
p27 null cells had a higher 3D mobility (Fig 14). 
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Figure 13: Cell paths in 3D environment.  Using the cell tracking software, the 
trajectories assumed by the cells in 3D collagen matrix were collected.
Figure 14: Evasion ability of p27wt and p27ko v-src transformed fibroblasts. 
Individual cells (7,5x103 cells/ml) were included in Matrigel or collagen I drops to 
evaluate their ability to exit from the matrices in response to chemotactic stimuli. 
The pictures shown a typical field of cells exited from the matrices drops 24 hours 
after the inclusion. The yellow dashed line indicates the drop edge.
Results
In order to evaluate  if  the differences in cell  migration observed in 3D systems could be 
ascribed to an impaired adhesive function during cell-ECM interactions, we tested p27+/+ and 
p27-/- v-src  cells  for  their  ability  to  attach  to  different  ECM substrates.  We performed  a 
CAFCA assay (Centrifugal  Assay for Fluorescence-based Cell  Adhesion;  Spessotto  et  al., 
2000) by seeding fluorescent labelled cells in flexible polyvinyl chloride miniplates (well’s 
surface comparable to the 96well plates) coated with vitronectin, fibronectin and collagen I 
(BSA as control) and then assaying their adhesion to substrates with reverse centrifugation. 
The  relative  number  of  bound  versus the  unbound cells  demonstrated  that  no  significant 
differences exist in the adhesive properties between p27+/+ and p27-/- v-src cells (Fig. 15).
 
Being v-src involved in focal adhesion turnover and in many signal transduction pathways 
activated after cell-ECM contact, we evaluated the activation of the main signalling pathways 
after  adhesion  of  p27+/+ and  p27-/- v-src  cells.  Since  most  of  motility  experiments  were 
performed in collagen I matrices, we analysed the cell signaling after 15, 30 and 60 minutes 
of adhesion to collagen coated plates (20µg/ml). The results showed no massive differences in 
the  total  amount  of  phosphorylated  proteins  between p27wt  and null  cell  clones,  even  if 
p27ko v-src cells tended to have a different activation kinetics of some signal transduction 
pathways. They in fact displayed a faster activation in particular of FAK, Stat3 and RhoA 
(evaluated using as read-out the phosphorylation of cofilin on S3, an accepted marker of the 
activation of Rho-ROCK signals) pathways at 15’of adhesion, whereas p27wt cells showed a 
more gradual activation during the different time points (Fig. 16).  
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Figure 15:  Adhesive  behaviour  of 
p27wt and  p27ko  v-src  transformed 
fibroblasts towards ECM substrates. 
Percentage  of  adherent  v-src 
transformed  fibroblasts  to  vitronectin 
(10µg/ml),  fibronectin  (10µg/ml), 
Collagen  I  (20µg/ml)  and  BSA  (as 
negative  control)  was  tested  using 
reverse centrifugation procedure. 5x103 
fluorescent labelled cells for well were 
seeded  in  flexible  polyvinyl  chloride 
96well-miniplates  in  sixth-plicate  and 
two different  clones for each genotype 
were  used.  The  differences  are  not 
statistically significant.   
Results
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Figure 16: Activation of signaling pathways after adhesion to collagen substrate. A. p27wt and ko cells 
were adhered for 15, 30 and 60 minutes to collagen coated dishes and then lysated and analyzed by western blot 
using phospho-antibodies specific to detect the phosphorylated residues of ERK1/2, Cofilin, FAK, Stat3 and 
AKT proteins. The total levels of the same proteins are also shown,. B. Quantification of the blots shown in A 
(as indicated) expressed as the ratio of the phosphorylated/total protein levels. Quantification was performed 
using the Odyssey software. 
Results
We next evaluated the ability of p27+/+ and p27-/- v-src cells to move and metastasize in vivo. 
To  this  aim the  mice  injected  subcutaneously  with  p27+/+ and  p27-/- v-src  cells  (n=9 for 
genotype) were analyzed for the presence of transformed cells in the spleen by RT-PCR with 
primers able to recognize the exogenous circulating cells as described in the methods section. 
Interestingly,  while  none  of  the  mice  injected  with  p27WT v-src  cells  (0/9)  showed  the 
presence  of  circulating  transformed  cells,  4/9  mice  injected  with  p27  null  cells  resulted 
positive (Fig. 17A,B). Moreover, the ability to settle and colonize distant sites was evaluated. 
In a pilot experiment we injected transformed fibroblasts in the tail veins of nude mice (n=4 
for genotype). The mice were sacrificed when they displayed breathing failure and fatigue (1 
month later), and just by macroscopic analysis of the lungs, we found a huge difference, with 
many tumor foci induced by p27-/- v-src cells and only few foci induced by p27+/+ v-src cells 
(Fig. 17C). 
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Figure 17:  In vivo motility of p27wt and p27null transformed fibroblasts.  A.  The mice injected s.c. 
with v-src cell clones as indicated (n=9 for genotype), were analysed for the presence of circulating cells 
performing an RT-PCR on RNAs extracts from mouse spleens and amplifying the resulted cDNA with 
primers specific for transformed cells. In the diagram the positive versus the negative spleens are displayed. 
B. A representative RT-PCR is shown. The ribosomal 18S subunit was used as control of RNA state and 
amount. As positive control (+), the cDNA derived by one primary tumor was used. C. Representative 
picture of lung metastasis formed 1 month after the injection of v-src transformed fibroblasts in the tail 
veins of nude mice (n=4 for genotype). 
Results
All the in vitro and in vivo results demonstrated that the absence of p27 in v-src transformed 
fibroblasts induces an increased proliferation coupled with a motile advantage that could be 
ascribed to the switch from a mesenchymal to an amoeboid-like motility.
4. p27 expression in p27-/- v-src cells reduced proliferation and tumor growth.
To definitively prove that the observed effects on v-src cell growth and motility were due to 
p27 itself, we reintroduced the p27 cDNA in p27KO null cells obtaining several clones and 
mass transfections. The only one strategy that allowed us to create clones stably expressing 
p27 at levels comparable to the endogenous protein, consisted in first transducing p27 in 3T3-
p27KO cells and then transforming them with v-src. Conversely, when we tried to re-express 
p27 wild type (p27WT) protein in v-src transformed p27 null cells we never obtained stable 
p27  independently  on  the  strategies  used  (data  not  shown).  However,  in  all  the  clones 
obtained  and  characterized,  the  v-src  protein  was  expressed  at  comparable  levels  as  by 
western blot evaluation (Fig. 18). 
To  reduce  the  v-src  induced  degradation  of  p27  wild  type  protein,  we  used  the  cDNA 
encoding for two less degradable form of p27, namely p27T187A and p271-170 (Fig 18). p27T187A 
carries a point mutation that results in the substitution of the threonine 187 with an alanine, 
thus impairing p27 degradation via the ubiquitin-dependent proteasome pathway (Montagnoli 
et al., 1999; Vlach et al., 1997). The deletion mutant p271-170 also lacks this residue, resulting 
in turn less degradable, and, as we previously demonstrated, retained the ability to block cell 
proliferation  while  loose  the  migratory  inhibitory  properties  of  the  wild  type  protein 
(Baldassarre  et  al.,  2005).  It  is  to  note  that  we obtained  some cell  clones  expressing the 
p271-170 mutant also by transducing the v-src p27KO clones 3 and 11. The biological behaviour 
of these clones was identical to the one observed in the p271-170 expressing cells derived from 
first  transducing  p27  in  3T3-p27KO cells  and  then  transforming  them  with  v-src.  These 
observations demonstrate that is the expression of p27 and not the way by which it is obtained 
to influence the biological behaviour of v-src transformed cells. For simplicity we will present 
in the next part of this thesis only the results obtained by the characterization of cell clones 
expressing p27T187A and p271-170 derived from first transducing p27 in 3T3-p27KO cells and then 
transforming them with v-src since this represents the only way to co-express p27T187A and v-
src in p27 null cells.
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Results
Proliferation assays of v-src transformed fibroblasts demonstrated that both p27 mutants were 
able to reduced cell proliferation to the levels observed in the p27WT v-src cells, as shown by 
growth curve obtained seeding 1x105  cells and counting them for other four days (Fig. 19A, 
B). 
Western blot analysis of cell cycle regulating proteins demonstrated that all the analyzed cell 
clones  expressed  similar  amount  of  cyclin  A,  cyclin  B1,  CDK1  and  CDK2 (Fig.  20A). 
However,  kinase  assays  demonstrated  that,  although  with  little  clonal  variability, 
reintroduction of both p27T187A and p271-170 strongly reduced the CDK activity associated to 
both cyclin  A and cyclin  B1 (Fig.  20B) confirming that  the expression of p27 is  able  to 
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Figure 18: p27-rescued clones selection. Western blot analysis of v-src and p27 expression in 
the indicated cell clones.  The slightly different molecular weight of p27T187A protein respect to 
the MW of endogenous p27 is due to the fact that the human protein was reintroduced in p27 
null mouse fibroblast. Vinculin was used to normalize the amount of proteins present in each 
lane. 
Figure 19: Proliferative behaviour of p27-rescued clones. The proliferation rate of p271-170  (A) 
and  p27T187A (B)  v-src  fibroblasts  was  tested  performing  growth  curve.  1x105cells/well  were 
seeded in duplicate in 6 well plates the day 1 and counted each day for 5 days.
Results
negatively  regulate  cell  proliferation  through  an  inhibitory  effect  on  the  cyclin/CDKs 
complexes activity. 
We next evaluated whether p27 could rescue also the transformed and tumorigenic potential 
in vitro and in vivo. First using soft agar assay, we showed that both p27T187A and p271-170 were 
able to reduce anchorage independent cell growth in term of both size and number of the 
colonies (Fig. 21A, B) demonstrating that during v-src transformation p27 is an important 
determinant for cell growth in semisolid media. 
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Figure 20: Cyclin-CDK expression and activity in v-src p27-rescued cell lines. A.  The expression of 
cyclin  A, cyclin  B1,  CDK1 and CDK2 in exponentially growing cells  was evaluated by western  blot. 
Vinculin was used to normalize the protein lysates.  B. A representative panel of kinase assay performed 
after immunoprecipitation for cyclin A (marker for S phase) and cyclin B1 (marker for G2-M phases). The 
Histon  H1  was  used  as  substrate  to  evaluate  the  rate  of  phosphorylation  (with  γATP-P32 radioactive 
labelling).
Figure 21: Analysis of  the anchorage-independent growth in p27-rescued clones. A. A soft agar assay 
was performed using two different clones for each cell lines. The diagram was obtained counting, with 10x 
objective, the colonies in 15 fields for each cell lines.  p27T187A  and p271-170 significantly reduced colonies 
number  compared  to  p27ko v-src  clones  (*: p=0,007 and  §:  p<0,0001). B. A  representative  picture  of 
colonies in 3D agar is reported to show the different colony sizes obtained by each cell line.
Results
This  effect  was  paralleled  by  in  vivo analysis  of  tumor  growth  in  nude  mice  after 
subcutaneously injection (n=6 for p27+/+ and p27-/- v-src cells, n=8 for p27T187A rescued mass 
transfections  and n=9 for  p271-170 rescued  clones)  showing  that  p27  expression  in  p27-/- 
transformed cells  significantly reduced the weight of tumors  formed by v-src transformed 
fibroblasts (Fig. 22).
  
5. p27T187A but not p271-170 rescued cell shape and motility.
We next analysed the 3D-cell shape and the motile behaviour of p27-rescued cell lines in 
order to verify whether p27T187A and p271-170 had any effects in the control of cell shape and 
motility. First, we included cells in 3D collagen matrices and analysed their morphology after 
10 hours from the inclusion. As described above (Fig. 9), also in p27-recued clones we can 
discern two diverse 3D cell shapes, namely elongated and rounded morphology. Interestingly, 
most p27T187A transformed cells clearly appeared to have the elongated and bipolar shape, in a 
proportion similar to the one observed in p27+/+ v-src cells (Fig. 23A). On the contrary, almost 
all p271-170 cells resulted rounded, as described for p27-/- v-src cells (Fig. 23A). 
This result was then confirmed by counting the rounded versus the elongated cells in five 
different  fields  for each experiment  (Fig.  23A, B).  p27T187A cells  displayed  about  50% of 
rounded and 50% of the elongated shape (50,4±16% versus 49,6%),  comparable  to p27+/+ 
transformed cells, having the 52,2±7,01% of elongated and 47,8% of rounded cells. On the 
contrary, 96±2,9% of the p271-170 population showed a rounded shape, resulting more similar 
to the p27-/- v-src cells (86±3,3% of rounded shape) (Fig. 23B). 
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Figure 22: In vivo tumor growth of 
p27-rescued fibroblasts.  1x106 cells 
were  injected  s.c. in  nude mice  and 
after  15  days  mice  were  sacrificed 
and  the  tumor  masses  evaluated.  In 
the  diagram  the  tumor  weight  is 
reported.  p27T187A  and  p271-170 
significantly  reduced  tumor  growth 
compared  to  p27ko  v-src  clones  (* 
and §: p<0,0001)
Results
The structural differences were evaluated by confocal microscopy analysis after staining of α-
tubulin (green) and polymerized actin (red). p27T187A cells, as the p27WT, appeared to have an 
elongated spindle  shape based both on microtubules and actin  stress  fibers  content,  while 
p271-170 expression was not able  to  rescue the morphological  phenotype  of p27 null  v-src 
fibroblasts and these cells still displayed a typical rounded amoeboid-like shape with cortical 
actin distribution (Fig 24). 
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Figure 23: Morphologic characterization of p27-rescued transformed cells. A. Representative pictures 
of the morphology acquired by p27T187A and p271-170 p27wt and p27ko v-src transformed fibroblasts after 10 
hours  of  inclusion  in  3D collagen  I  matrix.  The  pictures  were  collected  in  bright  field  using  a  10X 
objective. B. Quantification of the elongated and rounded cell population in the indicated cell lines shown 
as percentage  of  the total  cells  analyzed.  The results  represent  the mean (± SD) of  cells  counted in 5 
different fields for each independent experiment (n=3). The dead cells were excluded by the count.
Results
Interestingly also the behaviour of cell clusters support the data coming from the individual 
cells analysis. The spheroids obtained maintaining the cells in suspension for 24 hours, were 
included in 3D collagen matrix and a time lapse video microscopy was performed (Fig. 25 
and supplementary movies).  The expression of p27T187A reverted the p27KO phenotype  and 
cells in 3D displayed long cellular protrusion (Fig. 25) that allowed the cells to detach from 
the cell  cluster  using the mesenchymal  mechanism.  On the contrary,  p271-170-rescued cells 
showed a different clustering ability and detached from the spheroid in an amoeboid manner, 
showing a markedly spherical shape (Fig. 25), highly dynamic membrane blebs and squeezing 
through the collagen lattices in a very flexible way (supplementary movies).
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Figure 24: Cytosckeletric structures in p27-rescued transformed cells in 3D matrix. Cells 
included in 3D collagen I matrix were evaluated 10 hours after the inclusion for their actin 
and tubulin content. The actin network was stained with Phallotoxin-AlexaFluor546 (RED), 
whereas for tubulin detection FITC-conjugated monoclonal anti-α-tubulin antibody (GREEN) 
was used. 
Results
6. Migration rate and invasive potential were reduced after p27T187A expression.
The different motility acquired by p27-rescued clones in 3D matrices was coupled by a higher 
ability of p271-170 cells  to evade from 3D matrices,  as demonstrated by evasion assays  of 
individual cells included in Collagen I and Matrigel drops. As shown in Fig. 26A, 24 hours 
after  inclusion  only  few p27+/+ v-src  and  p27T187A rescued  cells  were  present  outside  the 
matrix. Conversely, p271-170 expression was not able to reduce cell migration of p27 null v-src 
cells and many cells were present outside the drops in the same time frame (Fig. 26A). 
Counting all the evaded cells (five drops for each cell lines) we confirmed the result in both 
the  collagen  and  the  Matrigel  matrix,  suggesting  a  similar  motile  behaviour  in  both  the 
matrices (Fig. 26B). 
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Figure 25: Spheroid assay of p27T187A and p271-170 v-src cells in 3D collagen matrix. Spheroids obtained 
by seeding cells in Petri dish were included in 3D collagen matrix and evaluated in bright field by collecting 
one picture every 5 minutes for at least 12 hours. Here, photogram collected with a 20X objective after 3, 6 
and 9 hours are reported.  
Results
To analyse the in vivo invasive potential, we evaluated the presence of circulating transformed 
cells by analyzing the spleen of the mice injected subcutaneously with p27-rescued clones. 
After RT-PCR of RNA extracted from spleen, we performed a nested PCR with two different 
couples of primers in order to amplify the exogenous cDNAs and specifically detect only the 
injected transformed cells. This analysis showed that only 1/7 mouse injected with p27T187A-
rescued cells  displayed a positive spleen (corresponding to the 14,2%), whereas 3/5 mice 
injected with p271-170-rescued cells had circulating cancer cells (corresponding to the 60%) 
(Fig. 27).
- 64 -
Figure 26: Evasion ability of p27-rescued transformed fibroblasts. A. Individual cells 
(7,5x103 cells/ml) were included in Matrigel and collagen I drops to evaluate their ability to 
exit  from  the  matrices.  Typical  images  of  matrix  drops  incubated  for  24  hours  from 
inclusion at 37°C are shown. B. Quantification of the experiment shown in A. The number 
of cells evaded from matrix drops within 24 hours is reported. p27T187A  , but not  p271-170 
(p=ns), significantly reduces matrix cell evasion compared to p27ko cells (p<0,001). 
Results
Moreover, in order to assess the ability to colonize distant organs  in vivo and based on the 
observation obtained by our pilot experiment (Fig. 17C), we injected in the tail veins 4 mice 
with p27+/+ and p27-/-  v-src cells as control, 7 mice with two different p27T187A rescued cell 
lines and 6 mice with two different p271-170 rescued clones. The mice were sacrificed after 20 
days from injection. Lungs were fixed in Bouin’s solution and first macroscopically analyzed. 
In agreement with the results above reported, p27-/- v-src cells showed a higher ability to settle 
and create tumor foci in the lungs (an average of 10,5 macroscopic foci for mouse), while 
p27+/+ cells were much less aggressive (with none macroscopically evident focus) (Fig. 28A, 
B).  Interestingly,  mice  injected  with  p27T187A-rescued  cells  displayed  on  average  1,95 
foci/animal, while the p271-170 counterpart showed 6,41 foci (Fig. 28B). 
Together  these  results  demonstrate  that  p27  expression  at  least  in  v-src  transformed 
fibroblasts  is able  to reduce both cell  migration rate  in vitro and invasion ability  in vivo. 
Importantly,  p27 controls these functions by regulating cell plasticity and these effects are 
independent on its ability to block cell cycle progression.
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Figure 27: In vivo metastatization of p27-rescued transformed fibroblasts. A. Nude mice injected s.c. 
with the different cell clones were analysed for the presence of circulating cells by performing an RT-PCR 
analysis on spleen samples as reported in figure 18. In the diagram the positive (black) versus the negative 
(grey) spleens are displayed. B. The same results are shown as percentage of positive spleen versus total 
animals analysed.
Results
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Figure 28: In vivo lung colonization of p27-rescued transformed fibroblasts. A. Representative pictures 
of the ribcages of mice injected in the tail veins with p27wt and p27ko v-src cells and sacrificed after 20 
days.  While it  appears  “macroscopically”  tumors-free in the case of p27wt cells, in the case of p27ko 
injection many tumor foci and colonies are present on both lungs and on the ribcage wall, suggesting a 
severe respiratory dysfunction. B. Representative pictures of explanted lungs of nude mice injected in vein 
with p27T187A and p271-170-rescued compared to p27wt and p27ko v-src transformed fibroblasts. Lungs were 
fixed in Bouin’s solution. The red arrows pinpoint the presence of tumor foci. 
Results
7.  H-Ras transformation induces in p27-/-  the same proliferative advantage displayed 
after v-src over-expression.
Based on the interesting features differentially displayed by p27+/+ and p27-/- cells after v-src 
transformation,  we  asked  whether  the  proliferative  and  motile  behaviour,  as  well  as  the 
morphologic  plasticity,  linked  to  p27  expression  could  be  oncogene-specific  or  could  be 
reproduced by the activation of other oncogenetic signals. To this aim, we transduced 3T3-
p27+/+ and 3T3-p27-/- murine fibroblasts with Harvey-Ras oncogene (H-Ras) and different cell 
clones were selected. Similar levels of H-Ras were observed in the different cell clones and in 
both p27+/+ and p27-/- clones the activation of two downstream Ras kinases, ERK1 and 2, was 
readily observed (Fig. 29). In p27WT cells the endogenous p27 levels were not reduced by Ras 
transduction (Fig. 29 last lane).
The selected clones were characterized for their  growth ability by FACS analysis,  growth 
curve and MTT proliferation assay. As in the case of v-src transformation, the absence of p27 
was linked to a higher proliferation rate also in H-Ras transformed cells, as shown by the 
percentage of cells progressing along the S-phase in exponentially growing conditions (38,3% 
of p27-/- versus 17% of p27+/+ H-Ras cells (Fig. 30A) and by growth curve experiments (Fig. 
30B, C).
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Figure 29: Clones selection.  Western blot analysis of 
H-Ras, transduced cell clones. The expression of Ras, 
pERK1/2, total  ERK1/2 and p27 in the indicated cell 
lines  is  shown.  Vinculin  expression  was  used  as  a 
control of quality and quantity of the proteins present in 
each lane.
Results
Next we evaluated the effects of serum starvation and cell-cell contact inhibition (typical anti-
proliferative signals for normal cells) in p27+/+ and p27-/- H-Ras transformed fibroblasts (Fig. 
31).  H-Ras clones  were  serum starved for  24 hours  and then re-stimulated  with  medium 
containing 10% Fetal Bovine Serum (FBS) and harvested at the indicated time points (9,15 
and 21 hours). The FACS (Fig. 32A) and western blot (Fig. 31B) analyses demonstrated that 
H-Ras transformed cell lines still retained a certain sensitivity to growth factors depletion and 
both genotype  accumulate  in  G1 after  serum deprivation.  Even though both cell  lines  re-
entered the cell cycle with similar kinetics, p27 null cells progressed through the S and G2 
phase faster than the wt counterpart (Fig. 31A). In fact, already after 15 hours of release in 
complete medium, p27ko transformed cells were consistently accumulated in G2-M phases, 
as  confirmed  by the high  expression of  cyclinB1 (Fig.  31B),  and after  21 hours  resulted 
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Figure 30: Proliferative behaviour of H-Ras transformed cells. A. Cell distribution in the cell cycle phases 
was evaluated in exponentially growing cells by FACS analysis after PI staining. The numbers indicate the cell 
percentages  in  the  different  phases.  B. Growth  curve  of  H-Ras  transformed  fibroblasts  is  shown.  1x  105 
cells/well were plated in triplicate the day 0 and counted each day for 5 days. C. 1x103 cells/well were seeded in 
sixth-plicate in 96well plates to perform the MTT assay. Two different clones were used for each genotype. The 
results were obtained measuring and quantifying the colorimetric reaction at 560nm in Elisa plate reader each 
day for 4 days.   
Results
already accumulate  in  the  G1 phase  of  a  new cell  cycle,  whereas  p27wt  cells  were  still 
progressing through the G2-M phases (Fig. 31A,B). 
Then we asked whether the response to contact inhibition was similar in p27wt and ko Ha-
Ras  fibroblasts.  Interestingly,  while  p27wt  cells  retained  a  certain  sensitivity  to  growth 
inhibition after achievement of confluence, p27ko cells still proliferate (Fig. 31C) confirming 
the importance of p27 in the control of growth arrest induced by cell-cell contact.
Based  on  the  results  demonstrating  a  faster  progression  along  the  cell  cycle  of  p27KO 
transformed cells, we asked whether they properly progressed along the M-phase. To this aim, 
we synchronize cells through a double thymidine block followed by nocodazole treatment as 
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Figure 31: Proliferation after serum starvation and achievement of confluence in H-Ras transformed 
fibroblasts. A. FACS analysis of transformed cells after 24 hours of serum starvation (T0) and then released in 
complete medium for 9, 15 and 21 hours. B. Western blot analysis of cells treated as in A and evaluated for the 
expression of cyclinA, cyclinB1 and p27. C. FACS analysis of H-ras transformed cells after the achievement of 
confluence. The percentage of the cells in the different cell cycle phases is reported.
Results
reported in the methods section to block the cells in pro-metaphase. Cells were then released 
in complete medium from nocodazole block and analyzed by FACS after 30, 60, 90, 120 and 
180 minutes to follow their progression along mitosis (Fig. 32). 
Our data suggested that p27 absence did not alter the time to complete M phase in mouse 
fibroblasts transformed with Ras but conversely it rendered the cells more sensitive to the M 
phase block induced by nocodazole (Fig. 32). In fact the biggest difference between p27 wt 
and null cells was observed in nocodazole arrested cells in which the percentage of cells in the 
G2/M phase was significantly higher in p27ko cells (71%) respect to wt cells (65%). This 
effect is in line with our previous studies that demonstrated the lower MTs stability of p27ko 
cells due to the higher stathmin activity (Baldassarre et al., 2005). 
To test  the effective tumorigenic  potential  of H-Ras transformed cells  and to evaluate the 
effects of p27 expression in this context, we first analysed the ability to grow in an anchorage 
independent way using the soft agar assay. The obtained results demonstrated that p27-/- H-
Ras cells formed significantly more colonies in comparison to the wt counterpart  (Fig. 33). 
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Figure 32: Analysis of progression along M phase.  p27+/+ and p27-/- H-Ras cells were analysed for their 
ability to progress  along mitosis by FACS. Cells were  first  synchronized  with a  double thymidine block, 
followed by a nocodazole treatment in order to block the cells in pro-metaphase. Then cells were released in 
complete medium and analysed at the indicated time points. 
Results
        
We next analysed the in vivo ability of H-Ras transformed cells to grow and induce tumors. 
We injected nude mice with two different clones derived from p27wt and p27ko fibroblasts 
transformed with H-Ras. 
In a preliminary experiment conducted on  5 mice/genotype we demonstrated that 1x106 of 
p27ko-H-Ras  cells  formed  in  all  mice  a  visible  tumor  after  12  days  from  the  initial 
subcutaneous injection of the cells while the same number of p27wt-H-Ras cells did not form 
tumors. 
For this reason in the next experiment we injected 2x106 p27wt or ko-H-Ras cells (Fig. 34). 
Under these conditions, tumors from p27ko-H-Ras cells became visible at day 10, while at the 
same time point the p27wt-H-Ras formed only very small tumors often not even appreciable 
at  the  palpation.  Mice  were  sacrificed  for  humanitarian  reasons  when  the  biggest  tumor 
reached the volume of approximately 800 mm3, 22 days after  cells injection. At this time 
point all  animals  of the experiment  were sacrificed and tumors  excised and analyzed.  As 
shown in figure 35, p27ko-H-Ras cells formed tumors bigger in size (Fig. 34A, B) and weight 
(0,96g versus 0,047g of p27wt cells. Fig. 34C) compared to the wt counterpart. No significant 
difference was observed between the two different clones used for each genotype (data not 
shown).
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Figure 33:  Analysis  of  anchorage 
independent  growth  in  H-Ras 
transformed cells.  2x103 cells were plated 
in  top  agar  (0,4%  top,  0,6%  bottom)  and 
allowed  to  form  colonies.  After  12  days, 
colonies number was estimated by counting 
15  different  field  for  each  cell  line.  The 
differences  are  highly   significant 
(p<0,0001).
Results
 
8. p27-/- fibroblasts displayed an increased cell motility also after H-Ras transformation. 
To evaluate whether H-Ras transformed cells were differentially able to migrate or invade the 
ECM components as observed in v-src model,  p27+/+ and p27-/-  fibroblasts were analysed in 
Matrigel evasion assay and in haptotactic-like migration assay toward fibronectin (Fig. 35). 
The results demonstrated that the absence of p27 conferred higher ability to exit from 3D 
matrices, as shown in Figure 35A, since p27-/- H-Ras cells are consistently present outside the 
matrigel  drops after  2 days  from inclusion,  whereas  p27+/+ cells  are  still  entrapped in  the 
matrix (Fig. 35A). Moreover, p27-/- H-Ras cells displayed also an increase in the migration 
rate in haptotactic-like experiments, compared to p27 wt counterpart (Fig. 35B).
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Figure 34:  In vivo growth of H-Ras transformed cells.  2x106 cells were injected subcutaneously in the 
flank of nude mice and mice have been sacrificed 22 days after. In A and  B representative picture of the 
injected  mice  (A)  and  explanted  tumors  (B)  are  shown.  C. The  graph  displays  the  tumor  weight.  Data 
represent the mean (±SD) of 5 mice/genotype. The differences between  p27wt and p27ko H-Ras cells are 
highly significant (p<1x10-4). 
Results
Further, we tested  in vivo motility by analysing the metastatization potential of p27+/+ and 
p27-/- H-Ras cells after injection in nude mice. Thus all the animals injected s.c. were analysed 
for the presence of circulating transformed cells in the blood and for the presence of distant 
metastasis in lungs by RT-PCR. Data shown that p27WT Ras cells were not able to invade the 
blood or the lungs while p27 null tumour cells were present both in the blood (3/5) and in the 
lungs (4/5) in p27ko of nude mice (part of these results are reported in Fig. 39), demonstrating 
that p27 absence increased the metastatic potential also of H-ras transformed fibroblasts.
9. p27-rescue in p27-/- H-Ras transformed cells: a more complicated scenario. 
In  order  to  understand  whether  the  expression  of  p27  protein  was  able  to  revert  the 
proliferative and motile phenotype shown in vitro and the oncogenic potential shown in vivo, 
we de novo expressed p27 cDNA into p27-/- H-Ras cells. We used a p27 wild type form and 
the  deletion  mutant  lacking  the  last  28  aminoacids  (p271-170)  described  above to  generate 
stable mass transfections (Fig. 36). 
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Figure 35: In vitro motility of H-Ras transformed cells. A. Matrigel evasion assay. Representative pictures 
showing the motile behaviour of p27wt and p27ko H-Ras cells included in 3D matrigel. The pictures were 
collected two days after the inclusion. The yellow dashed line indicates the drop edge.  B. Migration assay. 
The  diagram  shows  the  percentage  of  cells  migrated  toward  Fibronectin  substrate  in  transwell-based 
migration assay. Data were collected after 3, 5 and 7 hours from the seeding. 
Results
As in  the  case  of  v-src-induced  transformation  model,  we first  evaluate  the  proliferative 
behaviour of p27-rescued cell lines. Surprisingly, the expression of both p27 forms in cells 
already transformed by H-Ras, did not significantly reduce the in vitro proliferation rate, as 
demonstrated by growth curve and  MTT assay (Fig. 37A, B).
Although in soft agar assay p27 rescue induced a significant reduction in the numbers  of 
colonies compared to p27ko cells, the decrease was not sufficiently to completely revert the 
phenotype to the levels of p27wt cells. In fact, the colonies number induced by p27rescued 
cells  resulted  significantly  higher  compared  to  p27wt  cells  (Fig.  38A).  Moreover,  after 
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Figure 36:  p27-rescued  clones  selection.  p27ko  H-Ras  fibroblasts 
were transduced with p27wt and p271-170 (170), in order to obtain stable 
p27-rescued  mass  transfections.  In  the  western  blot  analysis  the 
expression of p27 and Ras is shown. Vinculin was used to normalize 
the blot.
Figure 37: Proliferative behaviour of p27-rescued clones. The proliferation rate of p27wt and 
p271-170-rescued H-Ras fibroblasts was tested performing growth curve (A) and MTT assay  (B) 
following the previously described procedures.
Results
injection in nude mice, the expression of p27 in both forms was not sufficient to reduce tumor 
growth (Fig. 38B). 
All  the  results  collected  about  the  proliferative  behaviour  suggest  that  additional  genetic 
alterations probably came out after H-Ras transformation and made the phenotype not more 
reversible with the expression of p27. 
Interestingly,  when  motility  of  p27-rescued  cells  was  analysed,  we  noticed  that  the 
reintroduction of p27wt cDNA but not p271-170 in H-Ras transformed cells strongly affected 
cell motility both in vitro (in evasion assay. Fig. 39A) and in vivo, as analysed by RT-PCR 
looking for circulating cells in the blood and for distant metastasis in lungs (Fig. 39B).
All together, the results collected using the H-Ras model well confirm those obtained after v-
src- transformation,  suggesting that  the proliferative and motile  advantage,  displayed after 
oncogene transformation in cells lacking p27, could be, at least in part, ascribed to common 
“oncogene-independent” pathways. 
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Figure 38: Analysis of tumorigenic potential in p27-rescued H-Ras transformed cells. A. 
Soft  agar  assay was performed to evaluate the anchorage-independent cell  growth.  Colonies 
were  counted  after  12 days  from seeding in  3D agar  and  15 field  for  each  cell  lines  were 
analysed.  B.  In  the  graph,  the  weight  of  tumors  induced  by  H-Ras  transformed  cells  are 
reported. For the experiment, 5 mice/genotype were used and 1x106 cells were injected s.c.
Results
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Figure 39: Characterization of motile behaviour in p27-rescued H-Ras transformed fibroblasts. A. The in 
vitro  motility was assayed by evasion assay. The exit of the cells from Matrigel drops was evaluated as the 
migration distance covered by the cells in 5 days.  To measure this parameter,  a crystal  violet  staining was 
previously  performed  and  representative  pictures  of  stained  drops  are  shown  below  the  diagram.  B. 
Representative nested PCRs performed on lungs and blood samples to detect exogenous cells are reported. 
Tumors were used as positive control. The results were confirmed performing PCR three times. C.  The results 
obtained by nested PCR are described as diagram. Each column represent the number of the obtained positive 
samples. 5 mice for genotype were analyzed.
Discussion
DISCUSSION
Uncontrolled cell proliferation as well as tissue invasion and metastasis represent two of the 
most important hallmarks in cancer (Hanahan and Weinberg, 2000). Metastasis is one of the 
main  cause  of  death  in  cancer  patients  affected  by  several  types  of  neoplasia  and  the 
progression  to  a  metastatic  tumor  phenotype  often  is  associated  to  a  worse  prognosis 
(Condeelis and Segall, 2003). Thus, one of the most successful strategy in cancer treatment 
could be represented by the combination of drugs that minimize the growth of existing tumors 
and, at the same time, limit their spread and diffusion to new sites. But, while treatments for 
primary  tumor  growth  have  clear  and  measurable  end  points,  the  development  of  anti-
metastasis treatments is more difficult  and will depend on a detailed understanding of the 
basic  steps  in  metastasis  formation,  beginning  at  the  primary  tumor  and ending  with  the 
establishment of new tumors in distant organs (Condeelis and Segall, 2003). 
The recent advances in techniques  of in vivo imaging and in the use and development  of 
animal models have clearly demonstrated the complexity of motile strategies and molecular 
adaptive responses displayed by the cells when placed in a more physiological context than 
classical experimental 2D environment (Friedl and Wolf, 2003; Wolf and Friedl, 2006; Sahai 
and  Marshall,  2003;  Condeelis  and  Segall,  2003).  Moreover,  emerging  evidences  have 
suggested that the several described migration mechanisms could be associated to a different 
ability of tumor cells to locally invade and/or to disseminate at distance, resulting differently 
able to induce metastasis in vivo.
Among all the molecular effectors that could display a role in tumor progression, particular 
interest has received the inhibitor of cyclin-CDK complexes p27kip1 (p27). p27 represents an 
ideal target displaying on one hand an inhibitory effect in cell cycle progression (Belletti et 
al.,  2005)  and  on  the  other  hand  by  reducing  cell  migration  both  in  vitro and  in  vivo 
(Baldassarre et al., 2005; Schiappacassi et al., submitted 2008; Yuan et al., 2007). Moreover, 
many human cancers express decreased amounts  of p27 compared to normal  tissues. The 
reduced  p27  expression  often  correlates  with  increased  tumor  aggressiveness  and  a  poor 
clinical outcome, and p27 protein levels result an independent prognostic factor for many of 
these tumors (Bloom and Pagano, 2003; Slingerland and Pagano, 2000; Philipp-Staheli et al., 
2001).
Thus, in this PhD thesis we have focused our attention on the role of p27 in the process of 
neoplastic transformation, pinpointing the effects strictly associated to p27 expression or to its 
absence. To this aim, we have used murine fibroblasts, previously immortalized with 3T3 
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protocol, derived from embryos wild type or knock out for the cdkn1b gene, encoding for the 
p27 protein. 3T3p27+/+ and p27-/- were then transformed by over-expression of v-src oncogene 
and different cell clones were analysed and fully characterized. H-Ras oncogene was used in 
the same manner to highlight common responses or different “oncogene-specific” effects.
1. p27 controls cell proliferation in transformed cell cultures and in vivo tumor growth. 
The characterization of in vitro proliferative behaviour demonstrated that p27 absence in v-src 
transformed cells correlated with an increased cell growth, as demonstrated by the S-phase 
cell  fraction  and  growth  curves.  The  same  result  was  also  observed  after  H-Ras 
transformation,  indicating  that  the  proliferative  advantage  could  be  an  “oncogene-
independent” effect. 
Whether this observation agrees with the role of p27 as tumor suppressor gene, it differs from 
the behaviour described in normal fibroblasts, in which the absence of p27 is not associated, 
at  least  apparently,  to  major  differences  in  the  proliferation  rate  (our  observations  and 
Nakayama et al., 1996). These observations suggest that the correct cell cycle progression in 
normal  p27-/-  cells  is  ensured  by  compensatory  and  redundant  mechanisms  that,  after 
challenging with oncogene stimuli, result no more sufficient to exert a full inhibition of cell 
cycle progression and, consequently,  to control the cell  proliferation.  These effects of p27 
seem to be mediated by a higher CDK1 and CDK2 activity that could be readily observed in 
p27-/- v-src  fibroblasts.  Moreover,  although  p27+/+ and  p27-/- embryonal  fibroblasts  are 
characterized by similar proliferative response to contact inhibition (Nakayama et al., 1996), 
we were able to highlight some differences after oncogenes transformation between the two 
genotypes. In particular, p27 expression resulted important to retain at least a partial activity 
in cell cycle inhibition after cell-cell contact in both v-src and H-Ras transformed cells. This 
observation is of extreme importance in the understanding of cell transformation process since 
loss  of  contact  inhibition  of  cell  growth  is  a  hallmark  of  cancer  cells.  Our  observation, 
although not completely confirmed in normal p27 null mouse fibroblasts, was not completely 
unexpected since previous work linked the contact-dependent block of cell proliferation to 
p27 expression (Polyak et al., 1994; Coats et al., 1996). Moreover, the observation that p27ko 
mice are bigger in size respect to the wild type littermate (Nakayama et al, 1996; Fero et al., 
1996; Kiokawa et al., 1996) suggests that also in vivo the cell-cell contact inhibition could not 
properly works. In accord with our in vitro and in vivo observations it has been demonstrated 
that  p27  null  animals  are  not  able  to  guarantee  the  same  response  after  oncogenetic 
challenges.  In fact,  even if p27 KO mice are relatively free of malignancies,  they show a 
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decreased tumor-free survival following γ-irradiation and an increased tumor-related mortality 
following treatment  with chemical  carcinogens,  with a dose dependent  effect  (Fero et  al., 
1998). 
The in vitro proliferative advantage of transformed p27 null cells was confirmed also in vivo, 
as demonstrated by the growth of xenograft sarcomas after s.c. injection in nude mice. In both 
v-src and H-Ras models, p27 absence is strictly associated to the induction of significantly 
bigger  masses.  But  while  in  v-src  transformation  p27-rescued  expression  impairs  tumor 
growth  and  completely  reverts  the  phenotype,  in  H-Ras  model  the  picture  appears  more 
complicated.  In  fact  the  expression  of  p27  is  not  sufficient  to  decrease  in  vivo growth, 
suggesting that other genetic alterations could be induced during Ras transformation. 
Moreover, the tumor suppressive activity of p27 is well supported by the data collected using 
an  adenoviral  approach  for  target  gene  therapy  in  glioblastomas  (Schiappacassi  et  al., 
accepted  for  publication  2008).  In  this  tumor  model,  the  over-expression of  p27 strongly 
impairs  the  in  vivo tumor  growth,  suggesting  that  p27 expression  could  be  an  important 
determinant  in  progression  of  several  tumor  types  (Schiappacassi  et  al.,  accepted  for 
publication 2008). 
2. p27 influences 3D cellular morph-dynamics and in vivo tumor dissemination.
The more interesting feature demonstrated in this study is represented by the description of a 
new p27 function in the control of cellular morph-dynamics. 
Tumor  cells  possess  a  broad  spectrum of  migration  mechanisms  to  infiltrate  surrounding 
matrices and to overcome tissue barriers, but they haven’t been clearly elucidated yet (Friedl 
and Wolf, 2003; Friedl, 2004). In our work, we have observed that after v-src transformation, 
3T3 fibroblasts can assume mainly two different cell morphologies in 3D collagen context. 
They  can  display  an  elongated  spindle-like  cell  shape,  typical  of  mesenchymal  cells, 
characterized  by  finger-like  protrusions  at  the  cellular  edges  and  actin  stress  fibers  and, 
moreover,  they  can  assume  a  rounded  amoeboid-like  cell  shape,  with  several  peripheral 
membrane ruffles, lost of the dendritic-like extensions and an actin cortical distribution. 
Interestingly, the percentage of cells that display the two different morphologies significantly 
changes according to p27 expression. The absence of p27 increases the number of rounded 
cells from the 52,2% to the 86%, whereas only the 14% of p27 null cells appear elongated. 
Till  now, no one study has demonstrated a correlation between the expression of any cell 
cycle inhibitors and cell shape, even if it is known that cell proliferation requires important 
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rearrangements in cell morphology to allow a proper cell division (Théry and Bornens, 2006; 
Meyers et al., 2006). The use of different p27 cDNAs allowed us to map the function of cell 
shape regulation in the C-terminus region of p27 protein. In fact, although p27 full length 
protein completely reverts the morphologic traits of p27null v-src cells, the deletion mutant 
lacking  the  last  28  aminoacids  (p271-170)  is  not  able  to  rescue  the  morphology  and, 
consequently, cells result almost all rounded and amoeboid. 
Importantly the different cell morphologies assumed by p27+/+ and p27-/- v-src cells in 3D 
matrices strongly influence the motile behavior and the migration rate. With the aid of time 
lapse video microscopy and cell tracking software to analyze migration parameters, we had 
the opportunity to study and directly visualized motility of individual and clustered cells in 
3D  environment,  mimicking  in  a  fascinating  way  a  “physiologic”  context.  Using  these 
experimental approaches, p27-/- v-src cells clearly display an amoeboid motility characterized 
by a very flexible cell  shape associated with highly dynamic membrane blebs and by the 
ability  to  rapidly  squeeze  through  the  matrix  lattices  overcoming  the  ECM  barriers. 
Conversely,  p27+/+ transformed cells mainly display a mesenchymal migration mechanism, 
establishing long cellular protrusions to generate the traction forces necessary for cell body 
advancing. Further, the amoeboid migration mechanism assumed by p27null cells induces a 
higher cells speed compared to the mesenchymal strategy and cells move faster than the wt 
counterpart. Importantly the in vitro behavior is associated in vivo to a high ability to settle at 
distant  sites and induce metastasis  formation,  suggesting that,  besides  the role  in  primary 
tumor  growth,  p27  absence  induces  a  more  aggressive  phenotype  also  by  increasing  the 
invasion capability and metastasis induction.  
Our previous observations have highlighted similar morphological and migration differences 
also in normal cells expressing or not p27 (Belletti et al., in preparation 2008). The absence of 
p27 or its down-regulation in fibroblasts results both in a more rounded cell shape compared 
to the typical elongated mesenchymal-like morphology of p27-expressing cells and in higher 
migration rates (Belletti et al., in preparation 2008). 
We have previously demonstrated that p27 binds and inhibits the MTs destabilizing protein 
Stathmin  and,  through  this  interaction,  p27 could  play  a  pivotal  role  in  in  vitro motility 
(Baldassarre et al., 2005). In fact by inhibiting Stathmin, p27 induces stabilization of the MT 
network  thus  impairing  cell  migration.  Recently  we have  demonstrated  that  p27/stathmin 
interaction controls also tumor cell invasion in  in vivo models, confirming our previous  in  
vitro results (Schiappacassi et al., accepted for publication 2008). 
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Whether p27/stathmin interaction could be involved also in the motile phenotype observed 
during v-src  transformation  is  still  to be determined,  although some of the collected  data 
strongly  suggest  this  possibility.  In  fact,  our  preliminary  results,  collected  using  a  small 
interference  adenoviral  system  able  to  strongly  reduce  stathmin  levels,  suggest  that  the 
migration rate of p27-/- v-src cells is significantly down-regulated, whereas the same siRNA 
does  not  significantly  change  the  motility  of  p27-expressing  cells.  Moreover,  we  have 
demonstrated  that  the  expression  of  p271-170 in  p27null  cells  does  not  revert  neither  the 
morphologic  traits  nor  the  migration  advantage  and we previously demonstrated  that  this 
deletion mutant is not able to bind and inhibit stathmin (Baldassarre et al.,  2005). Conversely 
a full length p27 cDNA completely rescues the phenotype both in vitro and in vivo. Thus, at 
least in part, the motility inhibition exerted by p27 seems to be mediated by its interaction 
with stathmin. 
Besides the p27 function in the control of MTs stability, we can not excluded a p27-mediated 
effect in the regulation of the actin cytoskeleton too. In fact, during cell migration both the 
tubulin and actin  cytoskeleton result  to play crucial  functions (Etienne-Manneville,  2004). 
Besson et  al.,  demonstrated  that  in over-expression conditions,  p27 directly interacts  with 
RhoA and inhibits its activity (Besson et al., 2004). These authors showed that p27 absence is 
associated to higher RhoA activity,  resulting in an increase of actin stress fibers and focal 
adhesions that in turn impairs motility in 2D experimental systems. An excessive adhesive 
potential is well known to reduce migration on 2D substrates, but in 3D environments, fully 
mature focal contacts are not usually observed (Friedl and Wolf, 2003). In 3D contexts, cells 
are  less  adhesive  and  can  switch  rapidly  from  a  migration  mechanisms  to  another,  a 
phenomen called cell plasticity (Friedl and Wolf, 2003; Condeelis and Segall, 2003). Thus, in 
3D matrices an up-regulation in RhoA activity could favour cell motility rather than impair it. 
RhoA is  known for its  ability  to form actin  stress fibers and focal adhesions through the 
recruitment and activation of its effectors mDia and the Rho-kinases, ROCK1 and ROCK2. 
But the recent analyses of motile behaviour in 3 dimensional environments have suggested 
that Rho-GTPases can display a major versatility and less “fixed” functions (Higashida et al., 
2004). For example a localized RhoA activation is required for the induction of membrane 
ruffling,  typical  morphological  trait  of  amoeboid  cells  (Kurokawa  and  Matsuda,  2005). 
Recently, an increase in RhoA activity, rather than impaired motility, was associated to the 
transition from a mesenchymal to an amoeboid motility in 3D systems (Sahai et al., 2007; 
Gadea et al., 2007). 
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Thus, in our model, we can speculate that the absence of p27 could induce high RhoA activity 
that in turn determines the switch to the amoeboid morph-dynamics observed in p27-/- v-src 
fibroblasts. Moreover, the acquirement of an amoeboid motility results more advantageous in 
a 3D environment because allows to easier pass through ECM lattices  in vitro (Friedl and 
Wolf,  2003)  and  overcome  tissue  barriers in  vivo.  The  data  we  collected  evaluating  the 
phosphorylation levels of cofilin (target protein phosphorylated on Ser3 by active RhoA) have 
highlighted a different kinetics of RhoA activity in p27-/- src cells compared to the wild type 
counterpart,  following  cell-ECM contact.  Interestingly,  in  the  same  assay  we observed  a 
different kinetics of FAK, AKT, STAT3 and ERK1,2 activation, suggesting that in p27 null 
cells there is a general modification of the signal trasduction pathways activated following 
cell  adhesion to ECM. One possible explanation for this observation resides in the recent 
demonstration  that  the  MT  network  controls  vesicular  transport  in  adherent  cells 
(Balasubramanian et al., 2007). It is thus possible that p27, by modifying MT stability through 
stathmin inhibition, control in turn the vesicular recycling of several proteins necessary for the 
proper control of cell growth and motility. Studies are in course in our laboratory to test this 
hypothesis in our model systems.
In conclusion, our results demonstrated that p27 expression is an important determinant both 
in  the  first  steps  of  cell  transformation  and  tumor  establishment  and  in  the  following 
progression to tumor  dissemination and colonization  of distant sites.  The fact  that  p27 in 
transformed cells controls not only cell cycle progression but also the regulation of cellular 
morph-dynamics makes it an attractive target for new anticancer therapies.
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